<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for the long‐term prevention of hereditary angioedema attacks - Beard, N - 2022 | Cochrane Library</title> <meta content="Interventions for the long‐term prevention of hereditary angioedema attacks - Beard, N - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013403.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for the long‐term prevention of hereditary angioedema attacks - Beard, N - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013403.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013403.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for the long‐term prevention of hereditary angioedema attacks" name="citation_title"/> <meta content="Nicole Beard" name="citation_author"/> <meta content="University of Canberra" name="citation_author_institution"/> <meta content="Michael Frese" name="citation_author"/> <meta content="University of Canberra" name="citation_author_institution"/> <meta content="Elena Smertina" name="citation_author"/> <meta content="University of Canberra" name="citation_author_institution"/> <meta content="Peter Mere" name="citation_author"/> <meta content="Macquarie University" name="citation_author_institution"/> <meta content="Constance Katelaris" name="citation_author"/> <meta content="Campbelltown Hospital and Western Sydney University" name="citation_author_institution"/> <meta content="Kerry Mills" name="citation_author"/> <meta content="University of Canberra" name="citation_author_institution"/> <meta content="kerry.mills@canberra.edu.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD013403.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/11/03" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013403.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013403.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013403.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Intravenous; *Angioedemas, Hereditary [chemically induced, drug therapy, prevention &amp; control]; Complement C1 Inhibitor Protein [adverse effects, therapeutic use]; Danazol [therapeutic use]; Quality of Life; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013403.pub2&amp;doi=10.1002/14651858.CD013403.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="9mpoajSI";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013403\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013403\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","ms","fa","pl","fr","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013403.pub2",title:"Interventions for the long\\u2010term prevention of hereditary angioedema attacks",firstPublishedDate:"Nov 3, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013403.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013403.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013403.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013403.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013403.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013403.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013403.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013403.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013403.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013403.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3052 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013403.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-sec-0078"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-sec-0067"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/appendices#CD013403-sec-0083"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/supinfo/CD013403StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/supinfo/CD013403StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for the long‐term prevention of hereditary angioedema attacks</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/information#CD013403-cr-0004">Nicole Beard</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/information#CD013403-cr-0005">Michael Frese</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/information#CD013403-cr-0006">Elena Smertina</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/information#CD013403-cr-0007">Peter Mere</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/information#CD013403-cr-0008">Constance Katelaris</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013403.pub2/information#CD013403-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Kerry Mills</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/information/en#CD013403-sec-0087">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 03 November 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013403.pub2">https://doi.org/10.1002/14651858.CD013403.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013403-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013403-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013403-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013403-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013403-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013403-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013403-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013403-abs-0001" lang="en"> <section id="CD013403-sec-0001"> <h3 class="title" id="CD013403-sec-0001">Background</h3> <p>Hereditary angioedema (HAE) is a serious and potentially life‐threatening condition that causes acute attacks of swelling, pain and reduced quality of life. People with Type I HAE (approximately 80% of all HAE cases) have insufficient amounts of C1 esterase inhibitor (C1‐INH) protein; people with Type II HAE (approximately 20% of all cases) may have normal C1‐INH concentrations, but, due to genetic mutations, these do not function properly. A few people, predominantly females, experience HAE despite having normal C1‐INH levels and C1‐INH function (rare Type III HAE). Several new drugs have been developed to treat acute attacks and prevent recurrence of attacks. There is currently no systematic review and meta‐analysis that included all preventive medications for HAE. </p> </section> <section id="CD013403-sec-0002"> <h3 class="title" id="CD013403-sec-0002">Objectives</h3> <p>To assess the benefits and harms of interventions for the long‐term prevention of HAE attacks in people with Type I, Type II or Type III HAE. </p> </section> <section id="CD013403-sec-0003"> <h3 class="title" id="CD013403-sec-0003">Search methods</h3> <p>We used standard, extensive Cochrane search methods. The latest search date was 3 August 2021. </p> </section> <section id="CD013403-sec-0004"> <h3 class="title" id="CD013403-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials in children or adults with HAE that used medications to prevent HAE attacks. The comparators could be placebo or active comparator, or both; approved and experimental drug trials were eligible for inclusion. There were no restrictions on dose, frequency or intensity of treatment. The minimum length of four weeks of treatment was required for inclusion; this criterion excluded the acute treatment of HAE attacks. </p> </section> <section id="CD013403-sec-0005"> <h3 class="title" id="CD013403-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes were 1. HAE attacks (number of attacks per person, per population) and change in number of HAE attacks; 2. mortality and 3. serious adverse events (e.g. hepatic dysfunction, hepatic toxicity and deleterious changes in blood tests). Our secondary outcomes were 4. quality of life; 5. severity of breakthrough attacks; 6. disability and 7. adverse events (e.g. weight gain, mild psychological changes and body hair). We used GRADE to assess certainty of evidence for each outcome. </p> </section> <section id="CD013403-sec-0006"> <h3 class="title" id="CD013403-sec-0006">Main results</h3> <p>We identified 15 studies (912 participants) that met the inclusion criteria. The studies included people with Type I and II HAE. The studies investigated avoralstat, berotralstat, subcutaneous C1‐INH, plasma‐derived C1‐INH, nanofiltered C1‐INH, recombinant human C1‐INH, danazol, and lanadelumab for the prevention of HAE attacks. We did not find any studies on the use of tranexamic acid for prevention of HAE attacks. </p> <p>All drugs except avoralstat reduced the number of HAE attacks compared with placebo. For breakthrough attacks that occurred despite prophylactic treatment, intravenous and subcutaneous forms of C1‐INH and lanadelumab reduced attack severity. It is not known whether other drugs have a similar effect, as the severity of breakthrough attacks in people taking drugs other than C1‐INH and lanadelumab was not reported. </p> <p>For quality of life, avoralstat, berotralstat, C1‐INH (all forms) and lanadelumab increased quality of life compared with placebo; there were no data for danazol. Four studies reported on changes in disability during treatment with C1‐INH, berotralstat and lanadelumab; all three drugs decreased disability compared with placebo. </p> <p>Adverse events, including serious adverse events, did not occur at a rate higher than placebo. However, serious adverse event data and other adverse event data were not available for danazol, which prevented us from drawing conclusions about the absolute or relative safety of this drug. No deaths were reported in the included studies. </p> <p>The analysis was limited by the small number of studies, the small number of participants in each study and the lack of data on older drugs, therefore the certainty of the evidence is low. Given the rarity of HAE, it is not surprising that drugs were rarely directly compared, which does not allow conclusions on the comparative efficacy of the various drugs for people with HAE. </p> <p>Finally, we did not identify any studies that included people with Type III HAE. Therefore, we cannot draw any conclusions about the efficacy or safety of any drug in people with this form of HAE. </p> </section> <section id="CD013403-sec-0007"> <h3 class="title" id="CD013403-sec-0007">Authors' conclusions</h3> <p>The available data suggest that berotralstat, C1‐INH (subcutaneous, plasma‐derived, nanofiltered and recombinant), danazol and lanadelumab are effective in lowering the risk or incidence (or both) of HAE attacks. In addition, C1‐INH and lanadelumab decrease the severity of breakthrough attacks (data for other drugs were not available). Avoralstat, berotralstat, C1‐INH (all forms) and lanadelumab increase quality of life and do not increase the risk of adverse events, including serious adverse events. It is possible that danazol, subcutaneous C1‐INH and recombinant human C1‐INH are more effective than berotralstat and lanadelumab in reducing the risk of breakthrough attacks, but the small number of studies and the small size of the studies means that the certainty of the evidence is low. This and the lack of head‐to‐head trials prevented us from drawing firm conclusions on the relative efficacy of the drugs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013403-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013403-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013403-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013403-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013403-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hu#CD013403-abs-0014">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013403-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013403-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013403-abs-0011">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013403-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013403-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013403-abs-0002" lang="en"> <h3>Drug treatments for the prevention of attacks of hereditary angioedema</h3> <p><b>What is hereditary angioedema and how is it treated?</b> </p> <p>Hereditary angioedema (HAE) is a serious and potentially life‐threatening condition that causes acute (sudden onset) attacks of swelling, pain and reduced quality of life. Several new medicines have been developed to treat acute attacks and prevent attacks from occurring. Some medicines are taken by mouth, whereas others are injected under the skin, or given by a vein directly into the blood. </p> <p>The medicines currently given for preventing HAE attacks are human C1 esterase inhibitor (often abbreviated as C1‐INH), berotralstat, lanadelumab, tranexamic acid, and danazol. In addition, we found a further medicine (avoralstat) that is currently being studied for its ability to prevent HAE attacks. </p> <p><b>What did we want to find out?</b> </p> <p>We investigated whether these medicines reduce the number of HAE attacks, and if any attacks that do occur are less severe than they would otherwise be. We also looked at whether people taking the medicines experienced a better quality of life, and whether the medicines caused unwanted side effects. </p> <p><b>What did we do?</b> </p> <p>We searched medical databases for clinical studies in children or adults with HAE that compared medications to prevent HAE attacks with placebo (a pretend treatment) or another medicine. </p> <p><b>What did we find?</b> </p> <p>We found 15 studies with 912 participants. All medicines except avoralstat reduced the number of HAE attacks, and even when attacks did occur, they were less severe for C1‐INH and lanadelumab (there were no results for the other medicines). We found that most medicines improved the quality of life of the people with HAE and were generally safe as they did not increase the number of serious and less serious side effects. </p> <p>We found no studies that tested tranexamic acid, and only one study tested danazol. There were also no studies that compared one medicine directly with another. This means that we cannot say for sure whether one medicine is better than another. </p> <p><b>Conclusions</b> </p> <p>C1‐INH, berotralstat, lanadelumab and danazol appear to reduce the risk of HAE attacks and increase the quality of life in people with HAE. The medicines do not seem to result in an increase in side effects. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>Our findings are limited by the small number of studies and the small number of participants in each study. Therefore, our confidence in these findings is low. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is current to 3 August 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013403-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013403-sec-0078"></div> <h3 class="title" id="CD013403-sec-0079">Implications for practice</h3> <section id="CD013403-sec-0079"> <p>Our data show that there is an evidence base for the use of avoralstat, C1 esterase inhibitor (C1‐INH; in various forms), lanadelumab and danazol in preventing hereditary angioedema (HAE) attacks. We were unable to find any studies of the use of tranexamic acid in preventing attacks. Current data show that avoralstat is ineffective in preventing attacks, whereas the other drugs (C1‐INH, danazol, lanadelumab, berotralstat) demonstrated efficacy. All drugs for which data were available (avoralstat, berotralstat, C1‐INH (in all forms), and lanadelumab), do not appear to increase the risk of adverse events including serious adverse events. However, the implications for practice resulting from our analysis are limited. There are insufficient studies available to draw firm conclusions about the absolute or relative efficacy of any drug compared with placebo or an active comparator. It is possible that danazol, subcutaneous C1‐INH and recombinant human C1‐INH are more effective than berotralstat and lanadelumab in reducing the risk of breakthrough attacks, but the small number of studies and the small size of the studies means that the certainty of the evidence is low. This and the lack of head‐to‐head trials prevented us from drawing firm conclusions on the relative efficacy of the drugs. No studies were available in people with Type III HAE, and as such, we can provide no conclusions about the efficacy or safety (or both) of interventions for this HAE type. </p> </section> <h3 class="title" id="CD013403-sec-0080">Implications for research</h3> <section id="CD013403-sec-0080"> <p>This analysis has highlighted the need for further investigation of all drugs for the prevention of HAE. We did not find a single trial that compared any drug with another drug. Both patients and clinicians need to know which drug is most effective and safest; the current data do not allow us to draw firm conclusions about the relative efficacy or safety of the various drugs available to patients. Furthermore, studies are needed in people with Type III HAE, and in populations of differing genetic and cultural backgrounds. </p> <p>We are cognisant of the fact that the rarity of HAE makes such trials difficult and expensive, and the rarity of the condition makes manufacturers less willing to invest in the conditions. We therefore hope that a national or international funding agency will see the urgent requirement for clarity in this area, and assist with sufficient funding to provide more certainty for both patients and their doctors. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013403-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013403-sec-0008"></div> <div class="table" id="CD013403-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Avoralstat compared with placebo for preventing hereditary angioedema attacks</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Avoralstat compared with placebo for preventing HAE attacks</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children or adults with Types I or II HAE </p> <p><b>Settings:</b> outpatient setting </p> <p><b>Intervention:</b> avoralstat </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with</b> </p> <p><b>avoralstat</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of HAE attacks</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.99</b> (0.92 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>110<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>990 per 1000</b> (920 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in number of HAE attacks</b> </p> <p>(per week)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>134</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of HAE attacks per week ranged across control groups from 0.59 to 1.27 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of HAE attacks per week in the intervention groups was <b>0.10 lower</b> (0.37 lower to 0.18 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No deaths reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.33</b> (0.01 to 7.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> (0 to 312) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of life</b><br/>Angioedema Quality of Life scale </p> <p>(lower score is better)<br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>93</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life ranged across control groups from −0.6 to −12.14 points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention groups was <b>6.78 points lower</b> (11.61 lower to 1.95 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disability</b> </p> <p>(any validated scale)</p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.85</b> (0.62 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>830 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>706 per 1000</b> (515 to 963) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HAE:</b> hereditary angioedema; <b>N/A:</b> not applicable; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision.<br/><sup>b</sup>Downgraded one level each for imprecision and inconsistency.<br/><sup>c</sup>Downgraded two levels for imprecision and one level for indirectness. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013403-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Berotralstat compared with placebo or active control for preventing hereditary angioedema attacks</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Berotralstat compared with placebo or active control for preventing HAE attacks</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children or adults with Types I or II HAE </p> <p><b>Settings:</b> outpatient setting </p> <p><b>Intervention:</b> berotralstat </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with berotralstat</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of HAE attacks</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.63</b> (0.39 to 1.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>37</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>910 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>573 per 1000</b> (355 to 910) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in number of HAE attacks</b> </p> <p>(per week)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>130</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks per week ranged across control groups from 0.55 to 0.95</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks per week in the intervention groups was <b>0.39 attacks lower</b> (0.74 lower to 0.05 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No deaths reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.77</b> (0.02 to 24.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>128<br/>(3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b> (1 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of life</b><br/>Angioedema Quality of Life scale<br/>(lower score is better)<br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>130</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life ranged across control groups from 3.18 points to −9.69 points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention group was <b>15.28 points lower</b> (29.42 lower to 1.14 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disability</b><br/>Standardised mean difference </p> <p>(lower is better)</p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability ranged across control groups from 1.51 to −1.95</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability in the intervention groups was <b>1.01 units lower</b> (1.62 lower to 0.40 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.03</b> (0.88 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>128</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>761 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>784 per 1000</b> (670 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HAE:</b> hereditary angioedema; <b>N/A:</b> not applicable; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision.<br/><sup>b</sup>Downgraded one level for imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013403-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>C1‐INH compared with placebo or active control for preventing HAE attacks</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children or adults with Types I or II HAE </p> <p><b>Settings:</b> outpatient setting </p> <p><b>Intervention:</b> C1‐INH(SC) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with C1‐INH(SC)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of HAE attacks</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.29</b> (0.16 to 0.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>810 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> (0 to 162) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in number of HAE attacks</b> </p> <p>(per week)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>45 <br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of HAE attacks per week in the control group was 0.93</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of HAE attacks per week in the intervention group was <b>0.81 lower</b> (0.98 lower to 0.64 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No deaths reported</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.34</b> (0.01 to 8.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>44<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> (0 to 187) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of life</b><br/>standardised mean difference </p> <p>(lower is better)</p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>36</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the control group was −0.87 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention groups was <b>0.29 units lower</b> (0.76 lower to 0.18 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disability</b> </p> <p>(any validated scale)</p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.03</b> (0.84 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>44</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>663 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>683 per 1000</b> (557 to 842) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>C1‐INH(SC):</b> subcutaneous C1 esterase inhibitor; <b>CI:</b> confidence interval; <b>HAE:</b> hereditary angioedema; <b>N/A:</b> not applicable; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision.<br/><sup>b</sup>Downgraded three levels for imprecision.<br/><sup>c</sup>Downgraded one level for imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013403-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Plasma‐derived C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>pdC1‐INH compared with placebo or active control for preventing HAE attacks</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children or adults with Types I or II HAE </p> <p><b>Settings:</b> outpatient setting </p> <p><b>Intervention:</b> pdC1‐INH </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with pdC1‐INH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of HAE attacks</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in number of HAE attacks</b> </p> <p>(per week)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>71</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks per week in the control group was 0.9</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks per week in the intervention group was <b>0.53 attacks lower</b> (0.58 lower to 0.48 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No deaths reported</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.54</b> (0.09 to 3.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>71<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> (5 to 164) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of life</b><br/>Angioedema Quality of Life Score<br/>(lower score is better) </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the control group was −6.86</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention group was <b>3.49 points lower</b> (10.86 lower to 3.88 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disability</b><br/>(any validated scale) </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.05</b> (0.78 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>71</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>561 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>589 per 1000</b> (438 to 797) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HAE:</b> hereditary angioedema; <b>N/A:</b> not applicable; <b>pdC1‐INH:</b> plasma‐derived C1 esterase inhibitor; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision.<br/><sup>b</sup>Downgraded three levels for imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013403-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Nanofiltered C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>C1‐INH‐nf compared with placebo or active control for preventing HAE attacks</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children or adults with Types I or II HAE </p> <p><b>Settings:</b> outpatient setting </p> <p><b>Intervention:</b> C1‐INH‐nf </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with C1‐INH‐nf</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of HAE attacks</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in number of HAE attacks</b> </p> <p>(per week)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>22</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of HAE attacks per week in the control group was 1.06</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of HAE attacks per week in the intervention group was <b>0.53 lower</b> (0.78 lower to 0.28 attacks per week lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No deaths reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of life</b><br/>standardised mean difference </p> <p>(lower is better)</p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the control group was 4.85 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention group was <b>0.91 units lower</b> (1.64 lower to 0.18 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disability</b> </p> <p>standardised mean difference</p> <p>(lower is better)</p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability in the control group was −0.71</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability in the intervention group was <b>0.84 units lower</b> (1.57 lower to 0.12 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>C1‐INH‐nf:</b> nanofiltered C1 esterase inhibitor; <b>CI:</b> confidence interval; <b>HAE:</b> hereditary angioedema; <b>N/A:</b> not applicable; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels for imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013403-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Recombinant human C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>rhC1‐INH compared with placebo or active control for preventing HAE attacks</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children or adults with Types I or II HAE </p> <p><b>Settings:</b> outpatient setting </p> <p><b>Intervention:</b> rhC1‐INH </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with rhC1‐INH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of HAE attacks</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in number of HAE attacks</b> </p> <p>(per week)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>32</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks in the control group was 1.8 per week</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks per week in the intervention groups was <b>0.92 attacks lower</b> (1.31 lower to 0.53 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No deaths reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.50</b> (0.06 to 34.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>29</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events reported in the placebo group, 1 event reported in the rhC1‐INH group.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of life</b><br/>standardised mean difference<br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disability</b><br/>(any validated scale)<br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.39</b> (0.71 to 2.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>29</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>398 per 1000</b> (203 to 772) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HAE:</b> hereditary angioedema; <b>N/A:</b> not applicable; <b>rhC1‐INH:</b> recombinant human C1 esterase inhibitor; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels for imprecision.<br/><sup>b</sup>Downgraded two levels for imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD013403-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Lanadelumab compared with placebo or active control for preventing hereditary angioedema attacks</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lanadelumab compared with placebo or active control for preventing HAE attacks</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children or adults with Types I or II HAE </p> <p><b>Settings:</b> outpatient setting </p> <p><b>Intervention:</b> lanadelumab </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lanadelumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of HAE attacks</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in number of HAE attacks</b> </p> <p>(per week)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>83</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks per week ranged across control groups from 0.37 to 0.49</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks per week in the intervention groups was <b>0.41 attacks lower</b> (0.48 lower to 0.35 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No deaths reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.88</b> (0.08 to 10.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>162</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b> (7 to 765) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of life</b><br/>standardised mean difference<br/>(lower is better)<br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>68</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the control group was −4.72 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention group was <b>0.91 units lower</b> (1.43 lower to 0.40 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disability</b><br/>Standardised mean difference<br/>(lower is better)<br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>64</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability in the control group was −5.42</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability in the intervention group was <b>1.38 units lower</b> (1.94 lower to 0.82 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.07</b> (0.77 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>158</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>840 per 1000</b> (710 to 980) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HAE:</b> hereditary angioedema; <b>N/A:</b> not applicable; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013403-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013403-sec-0009"></div> <section id="CD013403-sec-0010"> <h3 class="title" id="CD013403-sec-0010">Description of the condition</h3> <p>Hereditary angioedema (HAE) is a rare but serious condition that is characterised by random, recurrent attacks of swelling (angioedema). An attack is often heralded by a transient, non‐itchy rash called erythema marginatum (<a href="./references#CD013403-bbs2-0097" title="ZeerlederS , LeviM . Hereditary and acquired C1-inhibitor-dependent angioedema: from pathophysiology to treatment. Annals of Medicine2016;48(4):256-67.">Zeerleder 2016</a>). There may be prodromal symptoms (symptoms indicating onset), such as fatigue and feeling generally unwell before swelling occurs. At first, the swelling is typically painless and not itchy; however, it can become extremely painful and disabling. The swelling may affect the face and upper airway, intestinal mucosa, genitals and the extremities. Attacks peak at around 24 hours after onset and can last several days. Swelling of the airway is life‐threatening, as it can result in death by asphyxiation. Intestinal swelling causes abdominal pain and may be accompanied by nausea, vomiting and diarrhoea; signs and symptoms may present similar to acute bowel obstruction. A swelling attack may cause major fluid shifts, which may result in hypotension and shock. HAE attacks may be triggered by the following: 1. physical triggers such as surgery, injury or infection (<a href="./references#CD013403-bbs2-0067" title="FrankMM , GelfandJA , AtkinsonJP . Hereditary angioedema: the clinical syndrome and its management. Annals of Internal Medicine1976;84:580-93.">Frank 1976</a>); 2. pharmacological triggers such as oestrogens (<a href="./references#CD013403-bbs2-0068" title="FrankMM . Effect of sex hormones on the complement-related clinical disorder of hereditary angioedema. Arthritis and Rheumatism1979;22:1295-99.">Frank 1979</a>), and angiotensin‐converting enzyme (ACE) inhibitors (<a href="./references#CD013403-bbs2-0055" title="AgostoniA , CicardiM , CugnoM , ZingaleLC , GioffreD , NussbergerJ . Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology1999;44:21-5.">Agostoni 1999</a>); and 3. psychological factors such as stress or anxiety (<a href="./references#CD013403-bbs2-0098" title="ZotterZ , CsukaD , SzabóE , CzallerI , NébenführerZ , TemesszentandrásiG , et al. The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency. Orphanet Journal of Rare Diseases2014;9:44.">Zotter 2014</a>). However, in many cases, no precipitating factor can be identified. It is not known how many HAE attacks occur spontaneously, that is, do not have any precipitating factor. </p> <p>HAE affects approximately one in every 50,000 to 150,000 people (<a href="./references#CD013403-bbs2-0090" title="RocheO , BlanchA , CaballeroT , SastreN , CallejoD , Lopez-TrascasaM . Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Annals of Allergy, Asthma &amp; Immunology2005;94(4):498-503.">Roche 2005</a>; <a href="./references#CD013403-bbs2-0099" title="ZurawBL . Hereditary angioedema. New England Journal of Medicine2008;359:1027-36.">Zuraw 2008</a>), and follows an autosomal‐dominant pattern of inheritance in most people (<a href="./references#CD013403-bbs2-0071" title="GermenisAE , SpeletasM . Genetics of hereditary angioedema revisited. Clinical Reviews in Allergy and Immunology2016;51(2):170-82.">Germenis 2016</a>). Compared with more common causes of angioedema, such as allergies and ACE inhibitor medications, HAE is rare and diagnosis is frequently missed or delayed. A misdiagnosis can be fatal, as swelling of the upper airway as a result of HAE does not respond to medications routinely used for allergic swelling, such as adrenaline, corticosteroids or antihistamines. HAE should be considered when a patient presents with recurrent, isolated angioedema without urticaria and with a family history of similar attacks (<a href="./references#CD013403-bbs2-0075" title="HenaoMP , KraschnewskiJL , KelbelT , CraigTJ . Diagnosis and screening of patients with hereditary angioedema in primary care. Therapeutics and Clinical Risk Management2016;12:701-11.">Henao 2016</a>; <a href="./references#CD013403-bbs2-0087" title="MaurerM , MagerlM , IgnacioA , EmelAP , BetschelS , BorkK , et al. The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. World Allergy Organization Journal2018;11:5.">Maurer 2018</a>). However, 25% of people with HAE will not have a positive family history, as the condition often arises from a somatic mutation in the <i>SERPING1</i> gene. Untreated, HAE has a mortality rate of 15% to 33% (<a href="./references#CD013403-bbs2-0059" title="BorkK , WulffK , Steinmüller-MaginL , BraenneI , Staubach-RenzP , WitzkeG , et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy2018;73(2):442-50.">Bork 2018</a>). It is unclear what the mortality rate is for people who are treated for HAE. </p> <p>Most HAE attacks are associated with increased levels of bradykinin, a potent vasodilator. Binding of bradykinin to the bradykinin 2 (B2) receptor on blood vessels results in fluid extravasation and tissue swelling. Bradykinin is a low molecular weight peptide that is formed when kininogen is cleaved by the protease kallikrein. Active kallikrein is generated by a cleavage event that processes prekallikrein, which involves coagulation factor XII, another serum protease. The proteolytic activity of kallikrein is regulated by the C1 esterase inhibitor (C1‐INH), a serine protease inhibitor that is encoded by the <i>SERPING1</i> gene. People with Type I HAE (approximately 80% of all HAE cases) have insufficient amounts of C1‐INH; people with Type II HAE (approximately 20% of all cases) may have normal C1‐INH concentrations, but mutations in the <i>SERPING1</i> gene result in C1‐INH variants that can no longer control kallikrein (<a href="./references#CD013403-bbs2-0071" title="GermenisAE , SpeletasM . Genetics of hereditary angioedema revisited. Clinical Reviews in Allergy and Immunology2016;51(2):170-82.">Germenis 2016</a>). A few people, predominantly females, have HAE despite having normal C1‐INH levels and C1‐INH function (<a href="./references#CD013403-bbs2-0092" title="US HAE Association. Diagnosing HAE. www.haea.org/diagnosis.php (accessed 11 November 2018).">US HAE Association 2018</a>). These rare Type III or HAE nC1‐INH cases are often associated with mutations in the <i>F12</i> gene. The consequences of these mutations are poorly understood but are believed to affect the factor XII‐mediated processing of prekallikrein. Finally, since 2018, next‐generation sequencing has allowed the identification of mutations in five additional genes in people with HAE but who have normal C1‐INH levels and function: ANGPT1 (angiopoietin‐1), PLG (plasminogen), KNG1 (kininogen), MYOF (myoferlin) and HS3ST6 (heparan sulphate‐glucosamine 3‐O‐sulfotransferase 6) (<a href="./references#CD013403-bbs2-0057" title="BafunnoV , FirinuD , D'ApolitoM , CordiscoG , LoffredoS , LecceseA , et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. Journal of Allergy and Clinical Immunology2018;141(3):1009-17.">Bafunno 2018</a>; <a href="./references#CD013403-bbs2-0059" title="BorkK , WulffK , Steinmüller-MaginL , BraenneI , Staubach-RenzP , WitzkeG , et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy2018;73(2):442-50.">Bork 2018</a>; <a href="./references#CD013403-bbs2-0085" title="Lopes VeronezC , CsukaD , SheikhFR , ZurawBL , FarkasH , BorkK . The expanding spectrum of mutations in hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2021;9(6):2229-34. [DOI: 10.1016/j.jaip.2021.03.008]">Lopes Veronez 2021</a>). There are currently several abbreviations used for the HAE types. We have provided a table for reference (<a href="#CD013403-tbl-0008">Table 1</a>). </p> <div class="table" id="CD013403-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Hereditary angioedema nomenclature</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Abbreviation used in this review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Other abbreviations used in the literature</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type I HAE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type 1 HAE; HAE type 1; C1‐INH‐HAE (type 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type II HAE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type 2 HAE; HAE type 2; C1‐INH‐HAE (type 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type III HAE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type 3 HAE; HAE type 3; C1‐INH‐HAE (type 3)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>C1‐INH: C1 esterase inhibitor; HAE: hereditary angioedema.</p> </div> </div> <p>The clinical diagnosis of angioedema should be followed by laboratory testing for both complement component 4 (C4) concentrations and C1‐INH concentration and function. Two estimations at different time points are recommended. The combination of low C4 and low C1‐INH function has a 98% specificity for HAE caused by C1‐INH deficiency (<a href="./references#CD013403-bbs2-0072" title="GompelsMM , LockRJ , MorganJE , OsborneJ , BrownA , VirgoPF . A multicentre evaluation of the diagnostic efficiency of serological investigations for C1 inhibitor deficiency. Journal of Clinical Pathology2002;55(2):145-7.">Gompels 2002</a>; <a href="./references#CD013403-bbs2-0091" title="TarziMD , HickeyA , FörsterT , MohammadiM , LonghurstHJ . An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedema. Clinical and Experimental Immunology2007;149(3):513-6.">Tarzi 2007</a>). Routine genetic testing is not usually performed but is indicated in HAE cases where people have normal C1‐INH, and is occasionally used for prompt diagnosis in the neonate. </p> </section> <section id="CD013403-sec-0011"> <h3 class="title" id="CD013403-sec-0011">Description of the intervention</h3> <p>Treatments for the prevention of HAE attacks act through the supplementation of insufficient concentrations of C1‐INH, or by providing functional inhibitor proteins in the case of subfunctional C1‐INH. Functional C1‐INH can be provided either in the form of a concentrate prepared from plasma or as a recombinant protein (<a href="./references#CD013403-bbs2-0078" title="JohnsonNM , PhillipsMA . New treatments for hereditary angioedema. Skin Therapy Letters2018;23(1):6-8.">Johnson 2018</a>; <a href="./references#CD013403-bbs2-0084" title="LonghurstH . Optimum use of acute treatments for hereditary angioedema: evidence-based expert consensus. Frontiers in Medicine2018;4:245.">Longhurst 2018</a>). Both are administered as intravenous infusion or, more recently, as a subcutaneous injection. Traditionally, tranexamic acid and attenuated androgens have been the most commonly used pharmacological agents for the prophylaxis of HAE and are still the only forms of prophylaxis available in some countries. Tranexamic acid, an antifibrinolytic drug, interferes with the functions of plasminogen and plasmin; however, the mechanism of action in HAE is not well understood (<a href="./references#CD013403-bbs2-0095" title="WintenbergerC , Boccon-GibodI , LaunayD , FainO , KannyG , JeandelPY , et al. Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clinical and Experimental Immunology2014;178(1):112-7.">Wintenberger 2014</a>). Where other treatments are not available, tranexamic has been favoured in children because of a better adverse‐effect profile than attenuated androgens despite that its efficacy is considered modest (<a href="./references#CD013403-bbs2-0069" title="FrankMM , ZurawB , BanerjiA , BernsteinJA , CraigT , BusseP , et al. Management of children with hereditary angioedema due to C1 inhibitor deficiency. Pediatrics2016;138(5):e20160575.">Frank 2016</a>). Attenuated androgens, most commonly danazol, have been used for many years as an oral prophylactic medication in HAE. It is available in capsules of varying doses and is taken by mouth (<a href="./references#CD013403-bbs2-0066" title="Food and Drug Administration. Danocrine label ID: 3061327. www.accessdata.fda.gov/drugsatfda_docs/label/2011/017557s033s039s040s041s042lbl.pdf (accessed 20 December 2018):1-9.">FDA 2011</a>). Newer preventive approaches target kallikrein. The first of these to reach clinical practice is lanadelumab, a human monoclonal antibody targeting plasma kallikrein that is given subcutaneously (<a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a>; <a href="./references#CD013403-bbs2-0058" title="BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21.">Banerji 2018</a>). Another is the oral kallikrein inhibitor berotralstat (Orladeyo) (<a href="./references#CD013403-bbs2-0062" title="ChenX , KotianP , WilsonR , ParkerCD , BabuYS . Preclinical characterization of BCX7353, an oral plasma kallikrein inhibitor, for the treatment of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB230.">Chen 2017</a>). Several other molecules are being tested in clinical trials. These include a monoclonal anti‐FXII antibody (<a href="./references#CD013403-bbs2-0061" title="CaoZ , BiondoM , RayzmanV , HardyM , McDonaldA , BusfieldS , et al. Development and characterization of an anti-FXIIa monoclonal antibody for the treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB194.">Cao 2015</a>), and an oral plasma kallikrein inhibitor, avoralstat (<a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>; <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a>). </p> <p>The large number of different C1‐INH products can cause confusion. <a href="#CD013403-tbl-0009">Table 2</a> lists the drugs, their respective brand names and their routes of administration. </p> <div class="table" id="CD013403-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Drugs for the prevention of hereditary angioedema attacks</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Drug</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Brand</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Route of administration</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Avoralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not approved</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berotralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Orladeyo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1‐INH(SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haegarda</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SC</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1‐INH‐nf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cinryze</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravenous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pdC1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berinert</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravenous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>rhC1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ruconest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravenous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Danazol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Danocrine/Cyclomen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lanadelumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Takhzyro</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SC</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lysteda</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>C1‐INH: C1 esterase inhibitor; C1‐INH‐nf: nanofiltered C1 esterase inhibitor; C1‐INH(SC): subcutaneous C1 esterase inhibitor; HAE: hereditary angioedema; pdC1‐INH: plasma‐derived C1 esterase inhibitor; rhC1‐INH: recombinant human C1 esterase inhibitor. </p> </div> </div> <p>Interventions for the treatment of acute HAE attacks, such as C1‐INH concentrates for acute use (e.g. nanofiltered C1 esterase inhibitor (C1‐INH‐nf) (Cinryze), recombinant human C1 esterase inhibitor (rhC1‐INH) (Ruconest), icatibant (Firazyr) and ecallantide (Kalbitor)) will be covered in a separate Cochrane Review (<a href="./references#CD013403-bbs2-0070" title="FreseM , BeardN , MereP , KatelarisC , MillsK . Interventions for the treatment of acute hereditary angioedema attacks. Cochrane Database of Systematic Reviews2019, Issue 8. Art. No: CD013402. [DOI: 10.1002/14651858.CD013402]">Frese 2019</a>). </p> </section> <section id="CD013403-sec-0012"> <h3 class="title" id="CD013403-sec-0012">How the intervention might work</h3> <p>Treatment with recombinant human C1‐INH (rhC1‐INH) and plasma‐derived C1‐INH (pdC1‐INH) concentrates supplies functional inhibitor proteins in sufficient amounts to improve C1‐INH activity levels and ideally restores normal inhibitor activity in people with a C1‐INH deficiency (e.g. in cases with insufficient C1‐INH plasma levels or with non‐functional C1‐INH variants). The therapeutic effect of danazol is not fully understood; it may promote C4 and C1‐INH synthesis, it may cause a minor increase in C1 concentrations (thus improving the complement system) or it may prevent C1‐INH breakdown (<a href="./references#CD013403-bbs2-0065" title="FabianiJE , PaulinP , SimkinG , LeoniJ , PalombaraniS , SquiqueraL . Hereditary angioedema: therapeutic effect of danazol on C4 and C1 esterase inhibitors. Annals of Allergy1990;64(4):388-92.">Fabiani 1990</a>). Lanadelumab inhibits the kallikrein protease by blocking its substrate binding site (<a href="./references#CD013403-bbs2-0079" title="KennistonJA , FaucetteRR , MartikD , ComeauSR , LindbergAP , KopaczKJ , et al. Inhibition of plasma kallikrein by a highly specific active site blocking antibody. Journal of Biological Chemistry2014;289(34):23596-608.">Kenniston 2014</a>), which prevents the cleavage of high molecular weight kininogen into kininogen and bradykinin. Thus, lanadelumab can be used to control the production of excess bradykinin and, therefore, the subsequent development of acute HAE attacks (<a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a>; <a href="./references#CD013403-bbs2-0058" title="BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21.">Banerji 2018</a>). In summary, C1‐INH, danazol, lanadelumab, tranexamic acid and berotralstat prevent attacks by restoring normal C1‐INH activity or by inhibiting kallikrein. </p> </section> <section id="CD013403-sec-0013"> <h3 class="title" id="CD013403-sec-0013">Why it is important to do this review</h3> <p>Although HAE is rare, it is highly debilitating, may cause death, and is associated with high personal and economic burdens (<a href="./references#CD013403-bbs2-0086" title="LumryWR . Hereditary angioedema: the economics of treatment of an orphan disease. Frontiers in Medicine2018;5:22.">Lumry 2018</a>; <a href="./references#CD013403-bbs2-0094" title="WilsonDA , BorkK , SheaEP , RentzAM , BlausteinMB , PullmanWE . Economic costs associated with acute attacks and long-term management of hereditary angioedema. Annals of Allergy, Asthma and Immunology2010;104(4):314-20.">Wilson 2010</a>). The lives of people affected by this condition are disrupted by the apparently random nature of swelling attacks. HAE attacks can be very painful and are often associated with temporary disfigurement and severe morbidity (<a href="./references#CD013403-bbs2-0083" title="LonghurstH , BygumA . The humanistic, societal and pharmaco-economic burden of angioedema. Clinical Reviews in Allergy and Immunology2016;51(2):230-9.">Longhurst 2016</a>). Oedema of the upper airway in particular is life‐threatening. Thus, severe acute HAE attacks often result in presentations to the emergency department and, occasionally, in admission to hospital. Even with management at home, individuals may need several days away from school or work for recovery. Any effective preventive treatment for HAE should reduce the number of swelling attacks, improve the quality of life for people with HAE and prevent death. There are several options for the prevention of HAE attacks, but there is no systematic review of these treatments, and we currently do not know whether all preventive HAE treatments are equally effective and safe. This review presents the available evidence on the safety and efficacy of interventions for the long‐term prevention of HAE attacks, allowing evidence‐based decision‐making for health practitioners and patients. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013403-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013403-sec-0014"></div> <p>To assess the benefits and harms of interventions for the long‐term prevention of HAE attacks in people with Type I, Type II or Type III HAE. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013403-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013403-sec-0015"></div> <section id="CD013403-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013403-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials investigating interventions for the long‐term prevention of HAE attacks. We included blinded and open‐label trials. We excluded studies investigating interventions for the treatment of acute HAE attacks, as these are covered in another Cochrane Review (<a href="./references#CD013403-bbs2-0070" title="FreseM , BeardN , MereP , KatelarisC , MillsK . Interventions for the treatment of acute hereditary angioedema attacks. Cochrane Database of Systematic Reviews2019, Issue 8. Art. No: CD013402. [DOI: 10.1002/14651858.CD013402]">Frese 2019</a>). </p> </section> <section id="CD013403-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies involving children or adults with Type I, Type II or Type III HAE (HAE nC1‐INH) who were treated for the prevention of HAE attacks. We defined Type I HAE as HAE caused by insufficient amounts of C1‐INH; Type II HAE as HAE presenting with sufficient amounts of C1‐INH, but subfunctional or non‐functional C1‐INH; and Type III HAE as HAE with normal C1‐INH concentrations and function (<a href="./references#CD013403-bbs2-0092" title="US HAE Association. Diagnosing HAE. www.haea.org/diagnosis.php (accessed 11 November 2018).">US HAE Association 2018</a>). If the justification for designating the type of HAE is not specifically given, we accepted the diagnosis stated by the study authors. </p> </section> <section id="CD013403-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included any intervention that had been tested for the prevention of HAE attacks, including concentrated C1‐INH (either derived from blood or produced as a recombinant protein), as well as the drugs danazol, tranexamic acid, berotralstat and lanadelumab. There were no restrictions on dose, frequency or intensity of treatment. The minimum length of treatment was four weeks; this criterion excluded the acute treatment of HAE attacks. Furthermore, we included only studies that compared interventions with placebo or any active comparator, or both. </p> </section> <section id="CD013403-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>For all outcomes, we included the time points reported by individual studies, as long as they were not reporting on the treatment of an acute attack. Clinically relevant time study durations were four weeks or longer. The studies did not report their data at different time points, therefore we used the reported time point for each study in our analyses. Many studies reported data as mean number of events per week or mean number of events per month. In order to combine these data, we converted all 'per month' data to 'per week'. </p> <section id="CD013403-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013403-list-0001"> <li> <p>HAE attacks (number of attacks per person, per population) and change in number of HAE attacks </p> </li> <li> <p>Mortality</p> </li> <li> <p>Serious adverse events, such as hepatic dysfunction, hepatic toxicity and deleterious changes in blood tests (e.g. glucose tolerance, thyroid hormones, lipids, lipoproteins) </p> </li> </ul> </p> </section> <section id="CD013403-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013403-list-0002"> <li> <p>Quality of life (measured by any validated measure, such as Angioedema Quality of Life Questionnaire (AE‐QoL), Health‐Related Quality of Life Questionnaire for HAE (HAEQoL), 12‐Item Short Form Health Survey (SF‐12)) </p> </li> <li> <p>Severity of breakthrough attacks as reported by individual studies</p> </li> <li> <p>Disability (measured by any validated measure, such as Work Productivity and Activity Impairment Questionnaire). This includes any outcome that measures changes in the ability of people to attend and function well in the workplace and in recreational activities </p> </li> <li> <p>Adverse events, such as weight gain, mild psychological changes (irritability, nervousness, mood changes), increased body hair, gastrointestinal health, nausea, vomiting and flushing </p> </li> </ul> </p> </section> </section> </section> <section id="CD013403-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013403-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist conducted systematic searches of the following databases for randomised controlled trials and controlled clinical trials without language, publication year or publication status restrictions: </p> <p> <ul id="CD013403-list-0003"> <li> <p>Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web) (searched 3 August 2021); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 7) via the Cochrane Register of Studies Online (CRSO); </p> </li> <li> <p>MEDLINE (Ovid MEDLINE Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE) (1946 onwards) (searched 3 August 2021); </p> </li> <li> <p>Embase Ovid (from 1974 onwards) (searched 3 August 2021);</p> </li> <li> <p>CINAHL EBSCO (from 1982 onwards) (searched 3 August 2021).</p> </li> </ul> </p> <p>The Information Specialist searched the following trials registries on 3 August 2021:</p> <p> <ul id="CD013403-list-0004"> <li> <p>ClinicalTrials.gov (<a href="https://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="https://who.int/trialsearch" target="_blank">who.int/trialsearch</a>). </p> </li> </ul> </p> <p>The Information Specialist modelled search strategies for other databases on the search strategy designed for MEDLINE. Where appropriate, they were combined with adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled trials and controlled clinical trials (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Chapter 6, <a href="./references#CD013403-bbs2-0081" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Lefebvre 2021</a>). Search strategies for all databases are provided in <a href="./appendices#CD013403-sec-0084">Appendix 1</a>. </p> </section> <section id="CD013403-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched grey literature for evidence of studies that have not been published in peer‐reviewed journals, but did not find any unpublished studies. We had no need to contact manufacturers of pharmaceutical drugs for unpublished trials, as all such trials are registered in clinical trials databases. We also checked references of included studies for relevant publications. </p> </section> </section> <section id="CD013403-sec-0026"> <h3 class="title" id="CD013403-sec-0026">Data collection and analysis</h3> <section id="CD013403-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MF, NB) independently assessed each study for inclusion based on the inclusion criteria. We resolved any disagreements by consensus or discussion (or both) with a third review author (KM). We illustrated the study selection process in a PRISMA diagram (<a href="./references#CD013403-bbs2-0082" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GotzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine2009;6:e1000100.">Liberati 2009</a>). We listed all articles excluded after full‐text assessment in the <a href="./references#CD013403-sec-0095" title="">Characteristics of excluded studies</a> table along with the reason for their exclusion. </p> </section> <section id="CD013403-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>One review author (KM) extracted relevant data into a spreadsheet that was checked by another review author (ES). We resolved any disagreements by consensus. </p> <p>We collected the following information for each included study: study design; exclusions postrandomisation; losses to follow‐up; duration of study; unit of randomisation; country and setting; number of participants; age and sex of participants; participant inclusion and exclusion criteria; intervention and control group sample sizes, type, dose and duration of intervention; outcomes (as specified in the <a href="#CD013403-sec-0020">Types of outcome measures</a> section), funding source and declarations of interest declared by study authors. </p> </section> <section id="CD013403-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias of included studies using the Cochrane RoB 1 tool. This tool involves assessing the risk of selection bias, performance bias, detection bias, attrition bias, reporting bias and other bias (<a href="./references#CD013403-bbs2-0076" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.">Higgins 2017</a>). Two review authors (KM, NB) independently assessed the risk of bias, and we resolved disagreements by consensus or by reference to a third review author (MF). </p> </section> <section id="CD013403-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We calculated and reported dichotomous outcome measures, such as number of attacks, mortality, serious adverse events and adverse events, using risk ratios (RRs) with the associated 95% confidence intervals (CIs). We calculated and reported continuous outcome measures for change in number of attacks, quality of life and disability scores using the mean difference (MD) and the associated 95% CIs. If the included studies used different scales, we calculated a standardised mean difference (SMD) instead. Where the included studies reported only CIs or standard errors (SE), we converted these to standard deviations (SD) using the Review Manager 5 calculator (<a href="./references#CD013403-bbs2-0089" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). We based our calculations on an intention‐to‐treat (ITT) approach. </p> </section> <section id="CD013403-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>Our unit of analysis was the participant. We report on outcomes at a participant level.</p> <p>Due to the small number of studies available for analysis, we combined cross‐over and parallel studies in all analyses. To mitigate the heterogeneity that could result from this, we used a random‐effects analysis for the analyses. The cross‐over studies did not involve a washout period, however we did not consider this to cause carryover effects, as C1‐INH has a mean functional half‐life of approximately 39 hours (<a href="./references#CD013403-bbs2-0080" title="KunschakM , EnglW , MaritschF , RosenFS , EderG , ZerlauthG , et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion1998;38(6):540-9.">Kunschak 1998</a>), danazol has a mean elimination half‐life of approximately nine hours and avoralstat has a terminal half‐life that ranges from 12 hours to 31 hours. As such, the drugs are not expected to have carryover effects into the second cross‐over period. </p> <p>The inclusion of cross‐over trials with parallel trials in a meta‐analysis can give rise to a unit of analysis error. That is, the CIs around the effect sizes may be too large, giving a study too little weight in an analysis. However, given the paucity of studies available to us, and the conservative nature of the error, we considered the unit of analysis error to be of less significance than the resulting loss of information from excluding the studies. </p> </section> <section id="CD013403-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>Where measurements of variance (summary data) were missing, we imputed those values by taking the mean of the variance of other studies reporting on the same outcome using the same methodology. We did this for all studies with missing SDs/SEs. We also intended to undertake sensitivity analysis by removing studies with significant amounts of missing data (20% or more in a single outcome). As no study had high attrition, we did not perform this sensitivity analysis. We compared the rates of missing data between groups to determine if there was an imbalance between the groups. When it was possible, we carried out analyses using the ITT principle. We used per‐protocol data if ITT data were not available. </p> </section> <section id="CD013403-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>In first instance, we assessed the forest plots for each outcome to ensure there was overlap of the CIs of effect estimates. If no overlap existed, we planned to further assess the causes of heterogeneity. </p> <p>We assessed heterogeneity using Chi<sup>2</sup> and I<sup>2</sup> statistic, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013403-bbs2-0077" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>). In the context of the Chi² test, we used a P value of 0.10 or less to indicate significant heterogeneity. For our assessment of the significance of heterogeneity as measured using the I<sup>2</sup> statistic, we took direction and size of effect into consideration and used the following guidance for interpretation, provided in <a href="./references#CD013403-bbs2-0077" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>: </p> <p> <ul id="CD013403-list-0005"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> <p>When the I² statistic was in an area of overlap between two categories (e.g. between 50% and 60%), we considered differences in participants and interventions among the trials contributing data to the analysis (<a href="./references#CD013403-bbs2-0077" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>). </p> </section> <section id="CD013403-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting bias by creating a funnel plot using Review Manager 5 (<a href="./references#CD013403-bbs2-0089" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). Because funnel plots are not informative where there are fewer than 10 studies (<a href="./references#CD013403-bbs2-0077" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.">Higgins 2021</a>), we only undertook funnel plot analysis for outcomes containing 10 studies or more. </p> </section> <section id="CD013403-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We undertook meta‐analysis of data from included studies using a fixed‐effect model where possible. If factors in the trials clearly indicated that variance between studies were likely to be due to factors other than chance, we used a random‐effects model. We also used the random‐effects model in analyses where we combined parallel and cross‐over studies. </p> </section> <section id="CD013403-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We intended to undertake subgroup analyses for all outcomes, as follows:</p> <p> <ul id="CD013403-list-0006"> <li> <p>type of HAE (Type I HAE versus Type II HAE versus Type III HAE);</p> </li> <li> <p>baseline number of attacks (per week, per month, per year);</p> </li> <li> <p>different drugs;</p> </li> <li> <p>drug dose and drug frequency;</p> </li> <li> <p>age (children versus adolescents versus adults versus older people). Children were defined as aged 0 to 10 years, adolescents as 11 to 17 years, adults as 18 to 64 years, and older people as 65 years and above; </p> </li> <li> <p>sex (men versus women);</p> </li> <li> <p>comorbidities;</p> </li> <li> <p>concomitant medication versus no concomitant medication.</p> </li> </ul> </p> <p>Unfortunately, the studies did not report data for most of the subgroups mentioned above. We could only undertake subgroup analyses by dose. The baseline number of attacks was usually reported; however, the range of attacks per year (one to 56) within studies meant that a subgroup analysis by baseline attack numbers would have been meaningless. </p> </section> <section id="CD013403-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We intended to explore the impact of trials at high risk of performance and detection bias on the magnitude or direction of the overall effect by excluding from the analysis trials at high risk of bias. We defined studies to be at high risk of bias if we assessed the performance or detection bias at high risk of bias. However, most studies were at low risk of bias, and it was not meaningful to perform this sensitivity analysis. </p> <p>We also intended to undertake sensitivity analyses in which we removed studies with significant amounts of missing data (20% or more in a single outcome). However, no study had high attrition and therefore this analysis was unnecessary. </p> <p>We intended to look at the funding sources of clinical trials and undertake a sensitivity analysis by funding source, but pharmaceutical companies funded 14 trials. </p> </section> <section id="CD013403-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared summary of findings tables, which list key outcomes along with a degree of certainty according to the GRADE criteria (<a href="./references#CD013403-bbs2-0073" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490-4.">GRADE 2004</a>; <a href="./references#CD013403-bbs2-0074" title="GRADEpro GDT. Version accessed 20 December 2018. Hamilton, ON: McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>). Reported outcomes were the efficacy (risk of HAE attacks, change in HAE attacks, mortality, quality of life, disability) and safety (serious adverse events, adverse events) of interventions for the prevention of HAE attacks, as listed in <a href="#CD013403-sec-0020">Types of outcome measures</a>. We assessed and reported on the certainty of the evidence for each outcome. We graded the certainty as high, moderate, low or very low, based on the criteria of risk of bias, inconsistency, indirectness, imprecision and publication bias (<a href="./references#CD013403-bbs2-0073" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328:1490-4.">GRADE 2004</a>). We intended to report on the outcomes for each type of HAE (I, II and III) in separate summary of findings tables, but no studies included people with Type III HAE, and no included study differentiated between Type I and II HAE. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013403-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013403-sec-0039"></div> <section id="CD013403-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD013403-sec-0041"> <h4 class="title">Results of the search</h4> <p>The literature search revealed 3011 citations and we identified two additional records through other sources, of which 788 were duplicates (<a href="#CD013403-fig-0001">Figure 1</a>). After screening titles and abstracts of the remaining 2225 records, we excluded further 1980 records. We obtained the remaining articles as full texts. After application of the inclusion and exclusion criteria, we excluded 36 studies (37 records) with reasons, two studies (two records) were ongoing and one study (one record) was awaiting classification, which resulted in the inclusion of 121 records or clinical trial registry entries that reported on 15 clinical trials (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>; <a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a>; <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a>; <a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a>; <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>; <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>; <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a>; <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a>; <a href="./references#CD013403-bbs2-0012" title="RiedlMA , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , GiannettiBM , et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet2017;390(10102):1595-602. YangWH , LiHH , ChaseC , MoldovanD , Grivcheva-PanovskaV , HarperJR , et al. Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB231. ">NCT02247739</a>; <a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>; <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a>; <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a>). </p> <div class="figure" id="CD013403-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013403-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD013403-sec-0042"> <h4 class="title">Included studies</h4> <p>All 15 included studies were randomised, and most used placebo as the control (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>; <a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a>; <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a>; <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>; <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>; <a href="./references#CD013403-bbs2-0012" title="RiedlMA , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , GiannettiBM , et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet2017;390(10102):1595-602. YangWH , LiHH , ChaseC , MoldovanD , Grivcheva-PanovskaV , HarperJR , et al. Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB231. ">NCT02247739</a>; <a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>; <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a>; <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a>). Four studies directly compared different doses of the same medication (<a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a>; <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a>; <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a>), but no study compared one medication directly against another medication (head‐to‐head trials). Several studies compared several doses with placebo (<a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>; <a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a>; <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>). </p> <p>Seven were parallel studies (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>; <a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a>; <a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a>; <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>; <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a>), and seven were cross‐over studies (<a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a>; <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>; <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a>; <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a>; <a href="./references#CD013403-bbs2-0012" title="RiedlMA , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , GiannettiBM , et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet2017;390(10102):1595-602. YangWH , LiHH , ChaseC , MoldovanD , Grivcheva-PanovskaV , HarperJR , et al. Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB231. ">NCT02247739</a>; <a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>). <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a> was a partial cross‐over study whereby 60/75 participants crossed over after 14 weeks and 15/75 participants had continuous plasma‐derived C1‐INH (pdC1‐INH) liquid treatment for 28 weeks to assess long‐term safety. We only included data from the first 14 weeks of the SAHARA study. </p> <p>Two studies reported the efficacy and safety of avoralstat (<a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>; <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a>); three studies reported berotralstat (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>); six studies reported C1‐INH in various forms (C1‐INH‐nf: <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>; <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a>; subcutaneous: <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a>; pdC1‐INH: <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a>; rhC1‐INH: <a href="./references#CD013403-bbs2-0012" title="RiedlMA , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , GiannettiBM , et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet2017;390(10102):1595-602. YangWH , LiHH , ChaseC , MoldovanD , Grivcheva-PanovskaV , HarperJR , et al. Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB231. ">NCT02247739</a>); two studies reported lanadelumab (<a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a>; <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>); and one study reported danazol (<a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a>). <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a> compared human C1‐INH 2000 IU added to recombinant human hyaluronidase (rhH) 48,000 U with a lower dose of the same combination (C1‐INH 1000 IU plus rhH 24,000 U). </p> <p>Only one study reported on children specifically (<a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a>). None of the studies that included both children and adults presented results by age (<a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a>; <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a>; <a href="./references#CD013403-bbs2-0012" title="RiedlMA , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , GiannettiBM , et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet2017;390(10102):1595-602. YangWH , LiHH , ChaseC , MoldovanD , Grivcheva-PanovskaV , HarperJR , et al. Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB231. ">NCT02247739</a>). </p> <p>All studies included people with Type I and II HAE (thus no study included people with Type III HAE). No study presented data separately by HAE type. </p> <p>The 15 studies included 912 participants ranging from nine participants (<a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a>) to 126 participants (<a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>). </p> <p>Despite being an autosomal‐dominant condition, women tend to have more attacks and more severe attacks; this was reflected in the studies. Overall, the mean female representation in the studies was 69.3%, ranging from 56.0% to 87.5%. The mean body mass index (BMI) of people in the studies was 27.4. The range of BMI was not frequently reported, but in those studies that did report BMI range, the BMI varied from 18.6 to 49.5. </p> <p>See <a href="./references#CD013403-sec-0094" title="">Characteristics of included studies</a> table for details of the included studies. </p> </section> <section id="CD013403-sec-0043"> <h4 class="title">Excluded studies</h4> <p>We excluded 36 studies (37 records) (<a href="./references#CD013403-bbs2-0016" title="AabomA , AndersenKE , Perez-FernandezE , CaballeroT , BygumA . Health-related quality of life in Danish patients with hereditary angioedema. Acta Dermato-venereologica2015;95(2):225-6. ">Aabom 2015</a>; <a href="./references#CD013403-bbs2-0017" title="AbererW , MaurerM , BouilletL , ZanichelliA , CaballeroT , LonghurstHJ , et al. Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey. Allergy, Asthma, and Clinical Immunology2017;13:31. [DOI: 10.1186/s13223-017-0203-z]">Aberer 2017</a>; <a href="./references#CD013403-bbs2-0018" title="AgostoniA , MarasiniB , CicardiM , MartignoniGC . Intermittent therapy with danazol in hereditary angioedema. Lancet1978;1(8061):453. ">Agostoni 1978a</a>; <a href="./references#CD013403-bbs2-0019" title="AgostoniA , MarasiniB , CicardiM , MartignoniG , UzielL , PietrograndeM . Hepatic function and fibrinolysis in patients with hereditary angioedema undergoing long-term treatment with tranexamic acid. Allergy1978;33(4):216-21. ">Agostoni 1978b</a>; <a href="./references#CD013403-bbs2-0020" title="AgostoniA , CicardiM , MartignoniGC , BergamaschiniL , MarasiniB . Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology1980;65(1):75-9. ">Agostoni 1980a</a>; <a href="./references#CD013403-bbs2-0021" title="AgostoniA . The management of hereditary angioedema. Ricerca in Clinica e in Laboratorio1983;13(1):55-9. ">Agostoni 1983</a>; <a href="./references#CD013403-bbs2-0022" title="Aygören-PürsünE , Martinez SaguerI , KreuzW , KlingebielT , SchwabeD . Risk of angioedema following invasive or surgical procedures in HAE Type I and II – the natural history. Allergy2013;68(8):1034-9. ">Aygören‐Pürsün 2013</a>; <a href="./references#CD013403-bbs2-0023" title="BakerJW , CraigTJ , RiedlMA , BanerjiA , FittsD , KalfusIN , et al. Nanofiltered C1 esterase inhibitor (human) for hereditary angioedema attacks in pregnant women. Allergy and Asthma Proceedings2013;34(2):162-9. ">Baker 2013</a>; <a href="./references#CD013403-bbs2-0024" title="BernsteinJA , LiHH , CraigTJ , ManningME , LawoJP , MachnigT , et al. Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks. Allergy, Asthma, and Clinical Immunology2019;15:13. [DOI: 10.1186/s13223-019-0328-3]">Bernstein 2019</a>; <a href="./references#CD013403-bbs2-0025" title="BirjmohunRS , HovinghGK , StroesES , HofstraJJ , Dallinga-ThieGM , MeijersJC , et al. Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema. Clinical Therapeutics2008;30(12):2314-23. ">Birjmohun 2008</a>; <a href="./references#CD013403-bbs2-0026" title="BlohméG . Treatment of hereditary angioneurotic oedema with tranexamic acid. A random double-blind cross-over study. Acta Medica Scandinavica1972;192:293-8. ">Blohmé 1972</a>; <a href="./references#CD013403-bbs2-0027" title="BorkK , BygumA , HardtJ . Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Annals of Allergy, Asthma &amp; Immunology2008;100(2):153-61. ">Bork 2008</a>; <a href="./references#CD013403-bbs2-0028" title="BorkK , HardtJ . Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. International Archives of Allergy and Immunology2011;154(1):81-8. ">Bork 2011</a>; <a href="./references#CD013403-bbs2-0029" title="BorkK , WulffK , WitzkeG , HardtJ . Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII). Allergy2017;72(2):320-4. ">Bork 2017</a>; <a href="./references#CD013403-bbs2-0030" title="BusseP , BakerJ , Martinez-SaguerI , BernsteinJA , CraigT , MagerlM , et al. Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients. Journal of Allergy and Clinical Immunology. In Practice2017;5(4):1142-5. ">Busse 2017</a>; <a href="./references#CD013403-bbs2-0031" title="ChyungY , VinceB , IarrobinoR , SextonD , TenHoorC , KennistonJ , et al. Results of a phase 1a, single ascending dose study of DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein under investigation for long term prophylaxis of hereditary angioedema. Allergy2014;69(S99):581. ">Chyung 2014</a>; <a href="./references#CD013403-bbs2-0032" title="CicardiM , CastelliR , ZingaleLC , AgostoniA . Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. Journal of Allergy and Clinical Immunology1997;2:194-6. ">Cicardi 1997</a>; <a href="./references#CD013403-bbs2-0033" title="Davis-LortonMA , BussePJ , BanerjiA , ShennakM , LumryWR , WednerHJ , et al. Pharmacodynamic effect of DX-2930 on plasma kallikrein in hereditary angioedema patients. Journal of Allergy and Clinical Immunology2016;137(2):AB252. ">Davis‐Lorton 2016</a>; <a href="./references#CD013403-bbs2-0034" title="DrouetC , DesormeauxA , RobillardJ , PonardD , BouilletL , MartinL , et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. Journal of Allergy and Clinical Immunology2008;121(2):429-33. ">Drouet 2008</a>; <a href="./references#CD013403-bbs2-0035" title="EudraCT 2009-010736-18. An open-label exploratory phase II study of the safety and prophylactic effect of a weekly 50 U/kg rC1INH treatment in asymptomatic patients with hereditary C1INH deficiency (HAE) – OPERA. clinicaltrialsregister.eu/ctr-search/trial/2009-010736-18/HU (first received 4 April 2009). ">EudraCT 2009‐010736‐18</a>; <a href="./references#CD013403-bbs2-0036" title="EudraCT 2010-019670-32. Pharmacokinetics and safety of human pasteurised C1-inhibitor concentrate (Berinert/CE1145) in subjects with congenital C1-INH deficiency. clinicaltrialsregister.eu/ctr-search/trial/2010-019670-32/IT (first received 19 December 2012). ">EudraCT 2010‐019670‐32</a>; <a href="./references#CD013403-bbs2-0037" title="FarkasH , CzallerI , CsukaD , VasA , ValentinS , VargaL , et al. The effect of long-term danazol prophylaxis on liver function in hereditary angioedema – a longitudinal study. European Journal of Clinical Pharmacology2010;66(4):419-26. ">Farkas 2010</a>; <a href="./references#CD013403-bbs2-0038" title="FarkasH , CsukaD , ZotterZ , VargaL , FustG . Prophylactic therapy in children with hereditary angioedema. Journal of Allergy and Clinical Immunology2013;131(2):579-82.e1-2. ">Farkas 2013</a>; <a href="./references#CD013403-bbs2-0039" title="FüstG , FarkasH , CsukaD , VargaL , BorkK . Long-term efficacy of danazol treatment in hereditary angioedema. European Journal of Clinical Investigation2011;41(3):256-62. ">Füst 2011</a>; <a href="./references#CD013403-bbs2-0040" title="HofstraJJ , Kleine BuddeI , vanTwuyverE , ChoiG , LeviM , LeebeekFW , et al. Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor®): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety. Clinical Immunology (Orlando, Fla.)2012;142(3):280-90. ">Hofstra 2012</a>; <a href="./references#CD013403-bbs2-0041" title="NCT01108848. Patient registry study of Berinert® in normal clinical practice. clinicaltrials.gov/show/NCT01108848 (first received 22 April 2010). ">NCT01108848</a>; <a href="./references#CD013403-bbs2-0042" title="NCT01467947. Postmarketing immunogenicity study in HAE subjects treated with Berinert. clinicaltrials.gov/show/NCT01467947 (first received 9 November 2011). ">NCT01467947</a>; <a href="./references#CD013403-bbs2-0043" title="NCT01576523. A study to evaluate the clinical pharmacology and safety of C1-esterase inhibitor administered by the subcutaneous route. clinicaltrials.gov/show/NCT01576523 (first received 12 April 2012). ZurawBL , CicardiM , LonghurstHJ , BernsteinJA , LiHH , MagerlM , et al. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. Allergy2015;70(10):1319-28. ">NCT01576523</a>; <a href="./references#CD013403-bbs2-0044" title="NCT01760343. A study to evaluate the safety and pharmacokinetics of two formulations of C1-esterase inhibitor. clinicaltrials.gov/show/NCT01760343 (first received 4 January 2013). ">NCT01760343</a>; <a href="./references#CD013403-bbs2-0045" title="SharmaK , LevyRJ , WassermanRL , JacobsonKW , LaudadioC , CraigTJ . Evaluation of prodromal symptoms concurrent with hereditary angioedema therapy. Journal of Allergy and Clinical Immunology2009;123(2 Suppl):S100. ">Sharma 2009</a>; <a href="./references#CD013403-bbs2-0046" title="SweetLC , JacksonCE , YanariSS , YottJB . Danazol therapy in hereditary angioedema. Henry Ford Hospital Medical Journal1980;28(1):31-5. ">Sweet 1980</a>; <a href="./references#CD013403-bbs2-0047" title="SzegediR , SzéplakiG , VargaL , ProhaszkaZ , SzeplakiZ , KaradiI , et al. Long-term danazol prophylaxis does not lead to increased carotid intima-media thickness in hereditary angioedema patients. Atherosclerosis2008;198(1):184-91. ">Szegedi 2008</a>; <a href="./references#CD013403-bbs2-0048" title="SzéplakiG , VargaL , ValentinS , KleiberM , KaradiI , RomicsL , et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2005;115(4):864-9. ">Széplaki 2005</a>; <a href="./references#CD013403-bbs2-0049" title="WangY , MartinP , LuP , SchranzJ . Pharmacokinetics (PK) and pharmacodynamics (PD) of c1 esterase inhibitor (c1-IHN) for prophylaxis of angioedema attacks in patients (PTS) with hereditary angioedema (HAE). Allergy2017;72(Suppl 103):148. ">Wang 2017</a>; <a href="./references#CD013403-bbs2-0050" title="WaytesAT , RosenFS , FrankMM . Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. New England Journal of Medicine1996;334(25):1630-4. ">Waytes 1996</a><a href="./references#CD013403-bbs2-0051" title="ZotterZ , CzallerI , CsukaD , SzaboE , KohalmiKV , VargaL , et al. Adverse effects of danazol prophylaxis in female patients with hereditary angioedema due to C1-INH deficiency (HAE-C1-INH). Allergy: European Journal of Allergy and Clinical Immunology2013;97:430. ">Zotter 2013</a>). Reasons for exclusion were generally wrong study design and wrong population. </p> <p>See <a href="./references#CD013403-sec-0095" title="">Characteristics of excluded studies</a> table for reasons of the excluded studies. </p> </section> <section id="CD013403-sec-0044"> <h4 class="title">Studies awaiting classification</h4> <p>One study is awaiting classification as we were unable to obtain a copy of the report (<a href="./references#CD013403-bbs2-0052" title="ZhangH . Long-term therapy of hereditary angioedema. Chung-Hua i Hsueh Tsa Chih1990;70(4):211-3. ">Zhang 1990</a>). See <a href="./references#CD013403-sec-0096" title="">Characteristics of studies awaiting classification</a> table for more information. </p> </section> <section id="CD013403-sec-0045"> <h4 class="title">Ongoing studies</h4> <p>We identified two ongoing studies (<a href="./references#CD013403-bbs2-0053" title="NCT03712228. A study to investigate CSL312 in subjects with hereditary angioedema (HAE). clinicaltrials.gov/ct2/show/NCT03712228 (first received 19 October 2018). ">NCT03712228</a>; <a href="./references#CD013403-bbs2-0054" title="NCT04656418. CSL312 (Garadacimab) in the prevention of hereditary angioedema attacks. clinicaltrials.gov/ct2/show/NCT04656418 (first received 7 December 2020). ">NCT04656418</a>). See <a href="./references#CD013403-sec-0097" title="">Characteristics of ongoing studies</a> table for more information. </p> </section> </section> <section id="CD013403-sec-0046"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias in the included studies over five domains: selection bias, performance bias, attrition bias, reporting bias and other potential sources of bias. See <a href="#CD013403-fig-0002">Figure 2</a> and <a href="#CD013403-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD013403-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013403-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013403-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013403-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013403-sec-0047"> <h4 class="title">Allocation</h4> <section id="CD013403-sec-0048"> <h5 class="title">Random sequence generation</h5> <p>Eight studies did not report on method of randomisation and were at unclear risk of selection bias (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a>; <a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a>; <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>; <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a>; <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a>; <a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>; <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a>). <a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a> was at high risk of selection bias because allocation was sequential. The remaining studies were at low risk of selection bias as they used a computer‐generated system (<a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>), a web‐based randomisation system (<a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>), or interactive response system to generate random sequence (<a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>; <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0012" title="RiedlMA , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , GiannettiBM , et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet2017;390(10102):1595-602. YangWH , LiHH , ChaseC , MoldovanD , Grivcheva-PanovskaV , HarperJR , et al. Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB231. ">NCT02247739</a>; <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a>). </p> </section> <section id="CD013403-sec-0049"> <h5 class="title">Allocation concealment</h5> <p>Nine studies did not report on concealment of allocation and were at unclear risk of selection bias (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a>; <a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a>; <a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a>; <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>; <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a>; <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a>; <a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>; <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a>). The remaining studies were at low risk of selection bias, as they used computer or interactive‐based systems to ensure that allocation could not be predicted (<a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>; <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>; <a href="./references#CD013403-bbs2-0012" title="RiedlMA , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , GiannettiBM , et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet2017;390(10102):1595-602. YangWH , LiHH , ChaseC , MoldovanD , Grivcheva-PanovskaV , HarperJR , et al. Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB231. ">NCT02247739</a>; <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a>). </p> </section> </section> <section id="CD013403-sec-0050"> <h4 class="title">Blinding</h4> <p>All but one study blinded the participants to their allocation. The exception was the <a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a> trial, an open‐label extension of the double‐blind <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a> trial. We judged the <a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a> to be at high risk of performance bias. The remaining studies were at low risk of performance bias (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>; <a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a>; <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a>; <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>; <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>; <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a>; <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a>; <a href="./references#CD013403-bbs2-0012" title="RiedlMA , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , GiannettiBM , et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet2017;390(10102):1595-602. YangWH , LiHH , ChaseC , MoldovanD , Grivcheva-PanovskaV , HarperJR , et al. Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB231. ">NCT02247739</a>; <a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>; <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a>; <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a>). </p> <p>Six studies reported that outcome assessors were blinded to study allocation and were at low risk of detection bias (<a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>; <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>; <a href="./references#CD013403-bbs2-0012" title="RiedlMA , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , GiannettiBM , et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet2017;390(10102):1595-602. YangWH , LiHH , ChaseC , MoldovanD , Grivcheva-PanovskaV , HarperJR , et al. Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB231. ">NCT02247739</a>; <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a>; <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a>). Both <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a> and <a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a> stated that outcome assessors were not blinded and were at high risk of detection bias. The remaining studies were at unclear risk of detection bias (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a>; <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a>; <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>; <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a>; <a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>). </p> </section> <section id="CD013403-sec-0051"> <h4 class="title">Incomplete outcome data</h4> <p>All studies were at low risk of attrition bias. In some cases, this was because there was no attrition (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a>; <a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a>; <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a>; <a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>); in other cases, attrition was low and evenly spread across groups or studies used an ITT analysis or both (<a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>; <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a>; <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>; <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>; <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a>; <a href="./references#CD013403-bbs2-0012" title="RiedlMA , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , GiannettiBM , et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet2017;390(10102):1595-602. YangWH , LiHH , ChaseC , MoldovanD , Grivcheva-PanovskaV , HarperJR , et al. Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB231. ">NCT02247739</a>; <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a>; <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a>). </p> </section> <section id="CD013403-sec-0052"> <h4 class="title">Selective reporting</h4> <p>We compared each of the included studies with its published protocol. Thirteen studies reported results for all outcomes defined in the respective protocols (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>; <a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a>; <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a>; <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>; <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>; <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a>; <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a>; <a href="./references#CD013403-bbs2-0012" title="RiedlMA , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , GiannettiBM , et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet2017;390(10102):1595-602. YangWH , LiHH , ChaseC , MoldovanD , Grivcheva-PanovskaV , HarperJR , et al. Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB231. ">NCT02247739</a>; <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a>; <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a>). <a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a> did not publish a protocol and was at unclear risk of reporting bias. We judged <a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a> at high risk of reporting bias. </p> </section> <section id="CD013403-sec-0053"> <h4 class="title">Other potential sources of bias</h4> <p>The rare nature of the condition meant that many studies were very small. Small studies tend to overestimate treatment effects, so this should be taken into consideration. </p> <p>We judged all included studies at low risk of other bias as we identified no other sources of bias. We considered the potential for cross‐over studies to bias outcomes due to carryover effects; however, the drugs used in cross‐over studies had very short half‐lives, and were, therefore, unlikely to have an impact on the second period of the cross‐over trial. Despite the potential for a unit of analysis error, we decided to combine data from cross‐over and parallel studies in order to maintain the maximum information. </p> </section> </section> <section id="CD013403-sec-0054"> <h3 class="title" id="CD013403-sec-0054">Effects of interventions</h3> <p>See: <a href="./full#CD013403-tbl-0001"><b>Summary of findings 1</b> Avoralstat compared with placebo for preventing hereditary angioedema attacks</a>; <a href="./full#CD013403-tbl-0002"><b>Summary of findings 2</b> Berotralstat compared with placebo or active control for preventing hereditary angioedema attacks</a>; <a href="./full#CD013403-tbl-0003"><b>Summary of findings 3</b> C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</a>; <a href="./full#CD013403-tbl-0004"><b>Summary of findings 4</b> Plasma‐derived C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</a>; <a href="./full#CD013403-tbl-0005"><b>Summary of findings 5</b> Nanofiltered C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</a>; <a href="./full#CD013403-tbl-0006"><b>Summary of findings 6</b> Recombinant human C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</a>; <a href="./full#CD013403-tbl-0007"><b>Summary of findings 7</b> Lanadelumab compared with placebo or active control for preventing hereditary angioedema attacks</a> </p> <section id="CD013403-sec-0055"> <h4 class="title">Primary outcomes</h4> <section id="CD013403-sec-0056"> <h5 class="title">Risk of hereditary angioedema attacks</h5> <p>Five studies comparing intervention with placebo reported on risk of HAE attacks (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a>; <a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>; <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a>). All interventions except avoralstat decreased the risk of HAE attacks; however, there were few studies for each drug (<a href="#CD013403-fig-0004">Figure 4</a>). At approved doses, C1‐INH compared with placebo showed fewer HAE attacks than berotralstat (<a href="./references#CD013403-fig-0014" title="">Analysis 1.2</a>) (<a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>). The RR for C1‐INH versus placebo was 0.29 (95% CI 0.16 to 0.50, 1 study, 85 participants; P &lt; 0.001) and for berotralstat versus placebo was 0.63 (95% CI 0.39 to 1.00; 1 study, 37 participants; P = 0.05). </p> <div class="figure" id="CD013403-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of hereditary angioedema attacks by drug (approved doses only)." data-id="CD013403-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of hereditary angioedema attacks by drug (approved doses only).</p> </div> </div> </div> <p><a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a> enroled nine participants in a study comparing danazol with placebo. The same nine people were randomised each 28‐day period to receive either danazol 200 mg capsules three times a day or placebo capsules three times a day for 28 days, for a total of 93 courses. During the 46 courses in which participants were taking danazol, there was only one HAE attack. In contrast, during the 47 courses of placebo, there were 44 HAE attacks. This was a reduction in attack rate from 93.6% to 2.2% (<a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a>). </p> <p>Several trials directly compared different doses of the same medication to one another (<a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a>; <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a>; <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a>). All of these trials compared different doses of C1‐INH. One trial reported the number of attacks as the rate of attacks (<a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a>); this trial showed no clear difference between the two doses of C1‐INH (RR 0.85, 95% CI 0.60 to 1.21; 1 study, 126 participants; <a href="./references#CD013403-fig-0018" title="">Analysis 1.6</a>). </p> <p>Eleven studies reported on change in number of HAE attacks per week (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>; <a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a>; <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>; <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>; <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a>; <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>; <a href="./references#CD013403-bbs2-0012" title="RiedlMA , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , GiannettiBM , et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet2017;390(10102):1595-602. YangWH , LiHH , ChaseC , MoldovanD , Grivcheva-PanovskaV , HarperJR , et al. Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB231. ">NCT02247739</a>; <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a>). For <a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>, we derived the SDs from the mean, the number of participants and the 95% CI of the intervention and control groups. <a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>, <a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>, <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>, and <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a> did not report SDs. For these studies, we imputed the SDs by taking the mean of all SDs in the remaining studies. </p> <p>When drugs were analysed for their ability to reduce the number of attacks per week, subcutaneous C1‐INH (C1‐INH(SC)) (<a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>) and rhC1‐INH (<a href="./references#CD013403-bbs2-0012" title="RiedlMA , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , GiannettiBM , et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet2017;390(10102):1595-602. YangWH , LiHH , ChaseC , MoldovanD , Grivcheva-PanovskaV , HarperJR , et al. Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB231. ">NCT02247739</a>) were the most effective drugs (i.e. they caused the largest reductions in weekly attack rates) (<a href="#CD013403-fig-0005">Figure 5</a>; <a href="./references#CD013403-fig-0020" title="">Analysis 2.2</a>). Avoralstat was no more effective than placebo, whereas berotralstat reduced the number of weekly attacks by an average of 0.39 (95% CI −0.74 to −0.05; 3 studies, 130 participants). C1‐INH(SC) reduced attacks by 0.81 per week (95% CI −0.98 to −0.64; 1 study, 90 participants), while nanofiltered C1‐INH reduced attacks by 0.53 (95% CI −0.78 to −0.28; 1 study, 44 participants) and pdC1‐INH by 0.53 per week (95% CI −0.58 to −0.48; 1 study, 113 participants). Recombinant human C1‐INH reduced weekly attacks by 0.92 (95% CI −1.31 to −0.53; 1 study, 96 participants) and lanadelumab reduced attacks by 0.41 (95% CI −0.48 to −0.35; 2 studies, 83 participants). The mean placebo risk of weekly attacks across all studies was 0.90 (range 0.37 to 1.80). </p> <div class="figure" id="CD013403-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Change in number of hereditary angioedema attacks per week by drug (approved doses only)." data-id="CD013403-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Change in number of hereditary angioedema attacks per week by drug (approved doses only). </p> </div> </div> </div> <p>We compared the 95% CIs of the meta‐analysis subgroups. Where the CIs did not overlap, we took this as indirect evidence of a significant difference between the interventions. Such indirect comparison of these results suggests that C1‐INH(SC) may be superior to avoralstat, berotralstat, pdC1‐INH and lanadelumab. Similarly, indirect evidence suggests that rhC1‐INH may be superior to avoralstat, berotralstat and lanadelumab. </p> <p>Three trials compared different doses of C1‐INH with one another for their relative ability to reduce the number of attacks per week (<a href="./references#CD013403-fig-0025" title="">Analysis 2.7</a>) (<a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a>; <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a>). Although all three trials individually found no reductions in attacks in response to higher doses, a meta‐analysis of the three studies combined revealed fewer attacks with a higher dose (MD −0.15, 95% CI −0.27 to −0.02; 3 studies, 153 participants).‐ </p> <p>Two studies reported on children and adolescents (<a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>; <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a>). <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a> enroled children aged six to 11 years and gave them either C1‐INH‐nf 1000 IU or 500 IU twice per week. Twelve participants took part in the trial. There was no clear difference in the number of attacks per week with the higher dose (MD −0.12, 95% CI −0.36 to 0.12; <a href="./references#CD013403-fig-0026" title="">Analysis 2.8</a>). The <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a> trial group published a post‐hoc analysis of its adolescent participants (age 12 to 17 years) in the double‐blind phase of the study (<a href="./references#CD013403-fig-0026" title="">Analysis 2.8</a>). Five participants received lanadelumab 300 mg (three participants every four weeks, two participants every two weeks) and four participants received placebo. There was no clear difference between lanadelumab and placebo in the number of attacks per week (MD −0.14, 95% CI −0.38 to 0.10). The number of participants is currently too low to make definitive statements. </p> </section> <section id="CD013403-sec-0057"> <h5 class="title">Mortality</h5> <p>There were no deaths in any study; therefore analyses were not possible.</p> </section> <section id="CD013403-sec-0058"> <h5 class="title">Serious adverse events</h5> <p>We analysed the number of people with serious adverse events (SAEs) in each arm of studies that reported this outcome. Serious adverse events were rare (<a href="#CD013403-fig-0006">Figure 6</a>). None of the placebo‐controlled studies reported a risk of SAEs that was different from placebo (<a href="./references#CD013403-fig-0027" title="">Analysis 3.1</a>) (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>; <a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a>; <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>; <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>; <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>; <a href="./references#CD013403-bbs2-0012" title="RiedlMA , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , GiannettiBM , et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet2017;390(10102):1595-602. YangWH , LiHH , ChaseC , MoldovanD , Grivcheva-PanovskaV , HarperJR , et al. Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB231. ">NCT02247739</a>; <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a>). No SAEs occurred in either group in <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>. We intended to report on individual SAEs, but there were so few events that this would not be meaningful. The two studies that compared different doses of the same medication with one another did not reveal clear differences in the occurrence of SAEs (<a href="./references#CD013403-fig-0028" title="">Analysis 3.2</a>) (<a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a>). </p> <div class="figure" id="CD013403-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Risk of serious adverse events compared with placebo by drug." data-id="CD013403-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of serious adverse events compared with placebo by drug.</p> </div> </div> </div> </section> </section> <section id="CD013403-sec-0059"> <h4 class="title">Secondary outcomes</h4> <section id="CD013403-sec-0060"> <h5 class="title">Quality of life</h5> <p>The most common measure of quality of life for people with HAE is the Angioedema Quality of Life (AE‐QoL) scale. This scale has been validated and is used to measure the change in the disease state from the patient's perspective (<a href="./references#CD013403-bbs2-0093" title="WellerK , MagerlM , Peveling-OberhagA , MartusP , StaubachP , MaurerM . The Angioedema Quality of Life Questionnaire (AE-QoL) – assessment of sensitivity to change and minimal clinically important difference. Allergy2016;71(8):1203-9.">Weller 2016</a>). The minimum clinically important difference (MCID) for the AE‐QoL total score is a reduction of 6 points (<a href="./references#CD013403-bbs2-0093" title="WellerK , MagerlM , Peveling-OberhagA , MartusP , StaubachP , MaurerM . The Angioedema Quality of Life Questionnaire (AE-QoL) – assessment of sensitivity to change and minimal clinically important difference. Allergy2016;71(8):1203-9.">Weller 2016</a>). Meta‐analysis of the studies that measured the AE‐QoL revealed a clinically significant improvement in quality of life for three of the four drugs (avoralstat (<a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>; <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a>), berotralstat (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>), and lanadelumab (<a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>); <a href="./references#CD013403-fig-0029" title="">Analysis 4.1</a>). Avoralstat reduced the AE‐QoL by 6.78 points (95% CI −11.61 to −1.95; 2 studies, 117 participants). Berotralstat reduced the AE‐QoL by an average of 15.28 points (95% CI −29.42 to −1.14; 3 studies, 130 participants), and lanadelumab reduced the AE‐QoL by 14.91 points (95% CI −21.89 to −7.92, 1 study, 117 participants), more than twice the cut‐off for clinical significance. In the <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a> trial, there was no clear difference with pdC1‐INH in the first cross‐over period (MD −3.49, 95% CI −10.86 to 3.88; 1 study, 60 participants), but in the second period there was an improvement in quality of life (MD −16.87, 95% CI −22.79 to −10.95; 1 study, 53 participants) (<a href="#CD013403-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD013403-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Change in Angioedema Quality of Life (AE‐QoL) Questionnaire scores." data-id="CD013403-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Change in Angioedema Quality of Life (AE‐QoL) Questionnaire scores.</p> </div> </div> </div> <p>The <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a> study reported on quality of life using the European Quality of Life Five Dimension (EQ‐5D) scale. This scale was reported as Health State Values and on the Visual Analogue Scale (VAS). The VAS is easier to interpret, and so we used this scale in our analysis. Overall, C1‐INH(SC) resulted in an increase in quality of life compared with placebo (MD 8.90, 95% CI 2.87 to 14.93; <a href="./references#CD013403-fig-0030" title="">Analysis 4.2</a>). </p> <p>Finally, <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a> reported on quality of life using the 36‐item Short Form (SF‐36 scale). Compared with placebo, C1‐INH‐nf increased quality of life (MD 9.04, 95% CI 2.32 to 15.76; 1 study, 32 participants; <a href="./references#CD013403-fig-0031" title="">Analysis 4.3</a>). No MCID has been established for this scale in people with HAE. Using the "half SD approach" to estimating an MCID (<a href="./references#CD013403-bbs2-0088" title="NormanGR , SloanJA , WyrichKW . Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Medical Care2003;41(5):582-92.">Norman 2003</a>), this would suggest that an MCID for this scale may be approximately 5 points. Based on this approach, C1‐INF‐nf may increase quality of life to a clinically meaningful degree. </p> <p>When we combined all reported quality of life measures using an SMD analysis, all drugs for which quality of life measurements were reported (avoralstat, berotralstat, C1‐INH (all forms), lanadelumab) led to an improvement in quality of life compared with placebo (<a href="./references#CD013403-fig-0032" title="">Analysis 4.4</a>; <a href="#CD013403-fig-0008">Figure 8</a>): avoralstat resulted in an SMD of −0.48 (95% CI −0.84 to −0.11; 2 studies, 117 participants), berotralstat resulted in an SMD of −0.86 (95% CI −1.67 to −0.05; 3 studies, 130 participants), C1‐INH (including <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>; <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a>) resulted in an SMD of −0.39 (95% CI −0.75 to −0.04; 3 studies, 162 participants) and lanadelumab resulted in an SMD of −0.91 (95% CI −1.43 to −0.40; 1 study, 68 participants). Taking 0.5 units as a measure of clinical significance (<a href="./references#CD013403-bbs2-0064" title="CohenJ . Statistical power analysis for the behavioral sciences. 2nd edition. New York (NY): Taylor &amp; Francis, 1988. [DOI: 10.4324/9780203771587] [ISBN: 9780203771587]">Cohen 1988</a>), both berotralstat and lanadelumab treatments resulted in clinically important improvements in quality of life. </p> <div class="figure" id="CD013403-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Change in quality of life (all scales) by drug." data-id="CD013403-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Change in quality of life (all scales) by drug.</p> </div> </div> </div> <p>The two studies comparing different doses of the C1‐INH(SC) with one another found no clear differences between the doses (<a href="./references#CD013403-fig-0033" title="">Analysis 4.5</a>) (<a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a>; <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a>). </p> </section> <section id="CD013403-sec-0061"> <h5 class="title">Severity of breakthrough attacks</h5> <section id="CD013403-sec-0062"> <h6 class="title">Continuous outcomes</h6> <p>Only two studies reported severity of breakthrough attacks on a continuous scale (<a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>); both studies used C1‐INH as the intervention and placebo as the control. The <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a> trial reported breakthrough attack severity for 40 IU/kg and 60 IU/kg; both doses were superior to placebo, with reductions in severity of around 0.3 points on a 0 to 3 scale (representing no symptoms ('0'); mild symptoms ('1'); moderate symptoms ('2'); or severe symptoms ('3')). <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a> compared C1‐INH‐nf 1000 IU to placebo, and also showed a reduction in attack severity compared with placebo (<a href="./references#CD013403-fig-0034" title="">Analysis 5.1</a>). </p> <p>In the three studies that compared different doses of the same medication with one another, there were no clear differences in attack severity between any comparisons, and a meta‐analysis of the three studies did not change this result (MD −0.35, 95% CI −1.08 to 0.38; 3 studies, 154 participants; <a href="./references#CD013403-fig-0035" title="">Analysis 5.2</a>) (<a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a>; <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a>). </p> </section> <section id="CD013403-sec-0063"> <h6 class="title">Dichotomous outcomes</h6> <p>Three studies used a 0 to 3 scale to report the severity of breakthrough attacks (<a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>; <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a>), but presented data as the incidence of mild, moderate, or severe attacks, or no attacks. The risk of a severe breakthrough attack was reduced in people taking C1‐INH or lanadelumab; both drugs reduced this risk by around 80% (<a href="./references#CD013403-fig-0036" title="">Analysis 5.3</a>). The chance that a participant would have no symptoms (i.e. the participant did not have any attacks) was higher during treatment with C1‐INH or lanadelumab (percentages of participants who did not experience an attack: 39% with C1‐INH versus 9% with placebo; 44% with lanadelumab versus 2% with placebo; <a href="./references#CD013403-fig-0039" title="">Analysis 5.6</a>). Indirect comparison of these drugs can be made by examining both the magnitude of the placebo‐controlled differences and the test for subgroup differences. By this method, C1‐INH and lanadelumab appeared to be equally effective for this outcome. </p> </section> </section> <section id="CD013403-sec-0064"> <h5 class="title">Disability</h5> <p>Five trials reported on changes in disability (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>; <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>; <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>) (<a href="#CD013403-fig-0009">Figure 9</a>). During C1‐INH(SC) treatment, the <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a> study reported a placebo‐controlled change in activity impairment (measured using the Work Productivity and Activity Impairment scale) of −20.01 points (95% CI −30.86 to −9.27), but as this study did not report the individual changes, these findings were not included in the meta‐analysis. <a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a> reported on changes in the SF‐36 Physical Functioning component during treatment with C1‐INH‐nf. The <a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a> and <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a> (both berotralstat) and <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a> (lanadelumab) trials reported changes in the Physical Functioning subscale of the AE‐QoL scale. </p> <div class="figure" id="CD013403-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Change in disability compared with placebo by drug (approved doses only) (standardised mean difference)." data-id="CD013403-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-09.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Change in disability compared with placebo by drug (approved doses only) (standardised mean difference). </p> </div> </div> </div> <p>C1‐INH‐nf treatment resulted in an improvement in disability during the trial period (SF‐36 Physical Functioning component summary: MD 6.80 points, 95% CI 1.36 to 12.24; 1 study, 32 participants; <a href="./references#CD013403-fig-0040" title="">Analysis 6.1</a>) (<a href="./references#CD013403-bbs2-0009" title="BernsteinJ , ManningM , LiH , WhiteMV , BakerJ , LumryWR , et al. Safety and efficacy of escalating doses of C1 esterase inhibitor [human] as prophylaxis in patients with hereditary angioedema (HAE). Annals of Allergy, Asthma &amp; Immunology2012;109(5):A29. BernsteinJA , LiHH , CraigTJ , LonghurstHJ , FarkasH , ManningME , et al. Placebo-controlled trials of C1-inhibitor (C1-INH) replacement therapy for routine prevention of attacks in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. DaynoJ , MillerDP , HautamakiE , NewcomerS , FittsD , LumryWR . Relationship between angioedema attacks and health-related quality of life outcomes in patients with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2014;133(2 Suppl):AB33. LumryW , ManningME , HurewitzDS , Davis-LortonM , FittsD , KalfusIN , et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. Journal of Paediatrics2013;162(5):1017-22.e1. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Health-related quality of life (HRQoL) in patients with hereditary angioedema (HAE) receiving nanofiltered C1 inhibitor (C1 INH-nf) for prophylaxis: results of a randomised, placebo-controlled, cross-over study. Allergy2014;69(S99):491. LumryWR , MillerDP , BeusterienK , HautamakiE , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving nanofiltered C1 inhibitor for prophylaxis: results of a randomized, placebo controlled cross-over study. Annals of Allergy, Asthma &amp; Immunology2013;111(5 Suppl 1):A105. LumryWR , MillerDP , NewcomerS , FittsD , DaynoJ . Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks. Allergy and Asthma Proceedings2014;35(5):371-6. RiedlM , ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) for the prophylaxis of hereditary angioedema attacks. Allergy: European Journal of Allergy and Clinical Immunology2011;94:420-1. ZurawB , BakerJ , HurewitzD , WhiteM , VeghA , BieloryL , et al. Open-label use of nanofiltered C1 esterase inhibitor (human) (CinryzeTM) for the prophylaxis of hereditary angioedema (HAE) attacks. Annals of Allergy, Asthma &amp; Immunology2010;105(5 Suppl):A100. ZurawBL , BussePJ , WhiteM , JacobsJ , LumryW , BakerJ , et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. New England Journal of Medicine2010;363(6):513-22. ZurawBL , KalfusI . Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. American Journal of Medicine2012;125(9):938.e1-e7. ">NCT01005888</a>). There is no MCID established for this component summary, but in children and adults with other conditions, the MCID was 10 points (<a href="./references#CD013403-bbs2-0060" title="BrigdenA , ParslowRM , GauntD , CollinSM , JonesA , CrawleyE . Defining the minimally clinically important difference of the SF-36 physical function subscale for paediatric CFS/ME: triangulation using three different methods. Health and Quality of Life Outcomes2018;16:202.">Brigden 2018</a>; <a href="./references#CD013403-bbs2-0096" title="WyrwichKW , TierneyWM , BabuAN , KroenkeK , WolinskyFD . A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Services Research2005;40(2):577-92.">Wyrwich 2005</a>). This suggests that for the SF‐36 physical component summary, the change in disability may not be clinically meaningful. </p> <p>Meta‐analysis of the berotralstat trials revealed a reduction in physical impairment in the AE‐QoL Physical Functioning subscale favouring berotralstat (MD −22.5 points, 95% CI −34.91 to −10.08; 2 studies, 50 participants; <a href="./references#CD013403-fig-0041" title="">Analysis 6.2</a>) (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>). The <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a> trial revealed a reduction in physical impairment using the AE‐QoL Physical Functioning subscale favouring lanadelumab (MD −30.55 points, 95% CI −37.55 to −23.55; 1 study, 64 participants; <a href="./references#CD013403-fig-0041" title="">Analysis 6.2</a>). The MCID for the AE‐QoL Physical Functioning subscale has not been established, but taking the "half standard deviation" approach suggested by <a href="./references#CD013403-bbs2-0088" title="NormanGR , SloanJA , WyrichKW . Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Medical Care2003;41(5):582-92.">Norman 2003</a>, this would suggest a difference of approximately 11.3 points (weighted mean of SDs in <a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a> and <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a> divided by two) and 10.9 points for <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>. By this measure, the placebo‐controlled change in quality of life for people receiving berotralstat was nearly double and for lanadelumab three times the cut‐off for an MCID. </p> <p>When analysed as SMDs, all three drugs showed 'large' effect sizes, as defined by <a href="./references#CD013403-bbs2-0064" title="CohenJ . Statistical power analysis for the behavioral sciences. 2nd edition. New York (NY): Taylor &amp; Francis, 1988. [DOI: 10.4324/9780203771587] [ISBN: 9780203771587]">Cohen 1988</a>, compared with placebo (C1‐INH‐nf: −0.84; berotralstat: −1.01; lanadelumab: −1.38). Tests for subgroup differences showed no clear differences between the subgroups (<a href="./references#CD013403-fig-0042" title="">Analysis 6.3</a>). </p> </section> <section id="CD013403-sec-0065"> <h5 class="title">Adverse events</h5> <p>Nine placebo‐controlled trials reported the incidence of adverse events (<a href="./references#CD013403-bbs2-0001" title="Aygören‑PürsünE , BygumA , Grivcheva‑PanovskaV , MagerlM , GraffJ , SteinerUC , et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. New England Journal of Medicine2018;379(4):352-62. BygumA , PanovskaVG , MaurerM , MagerlM , FarkasH , CicardiM , et al. Pharmacokinetic (PK) and pharmacodynamic (PD) effects of BCX7353 in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): results from APeX-1 study. Allergy2018;73(Suppl 105):723. FarkasH , Aygoren-PursunE , PanovskaVG , HuissoonA , KinaciyanT , MurrayS , et al. Relationship of target concentrations with efficacy: results from the APeX-1 study of Bcx7353. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S33. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. BCX7353 improves health-related quality of life in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE): findings from the APeX-1 study. Allergy2018;73(Suppl 105):724. SteinerUC , HuissoonA , BygumA , PanovskaVG , GompelsM , CancianM , et al. Analysis of gastrointestinal (GI) symptoms in patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) treated with BCX7353: results from APeX-1 study. Allergy2018;73(Suppl 105):724-5. ">APeX‐1</a>; <a href="./references#CD013403-bbs2-0002" title="AndersonJ , GagnonR , BestJ , MurrayS , IoccaH , SitzK . Reduction in attacks in hereditary angioedema (HAE) with berotralstat is consistent regardless of prior prophylactic treatment: a subgroup analysis of the phase 3 APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2):AB23. [DOI: 10.1016/j.jaci.2020.12.122]Aygören‑PürsünE , JohnstonD , BanerjiA , BernsteinJA , YangWH , FritzS , et al. Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study. European Journal of Allergy and Clinical Immunology2020;75(Suppl 109):457-8. [DOI: 10.1111/all.14508]GowerR , BusseP , BestJ , MurrayS , IoccaH , KinaciyanT . Berotralstat reduces use of on-demand medication in hereditary angioedema (HAE) patients previously treated with prophylactic therapies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB146. JacobsJ , Aygören-PürsünE , SitzK , TachdjianR , LiH , BestJ , et al. Berotralstat positively impact patient-reported satisfaction: results from the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S25. JohnstonD , BanerjiA , RiedlM , SoteresD , BersteinJ , BestJ , et al. Berotralstat improves patient-reported quality of life through 48 weeks in the phase 3 APeX-2 trial. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S22. LiHH , BestJ , MurrayS , IoccaH , TachdijanR . Berotralstat consistently demonstrates reductions in attack frequency in hereditary angioedema (HAE) irrespective of baseline attack rate: subgroup analysis from the APeX-2 trial. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB22. WednerH , ZurawB , AndersonJ , CraigT , KianiS , IoccaH , et al. Berotralstat reduces attacks in patients with hereditary angioedema (HAE): APeX-2 trial 48 week results. Annals of Allergy, Asthma &amp; Immunology2020;125(5 Suppl):S14. WednerJH , Aygören-PürsünE , BernsteinJ , CraigT , GowerR , JacobsJS , et al. Randomized trial of the efficacy and safety of berotralstat (BCX7353) as an oral prophylactic therapy for hereditary angioedema: results of APeX-2 through 48 weeks (part 2). Journal of Allergy and Clinical Immunology. In Practice2021;9(6):P2305-14.E4. ZurawB , LumryWR , JohnstonDT , Aygören-PürsünE , BanerjiA , BernsteinJA , et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. Journal of Allergy and Clinical Immunology2021;148(1):164-72.e9. [DOI: 10.1016/j.jaci.2020.10.015]">APeX‐2</a>; <a href="./references#CD013403-bbs2-0003" title="OhsawaI , HondaD , SuzukiY , FukudaT , KohgaK , MoritaE , et al. Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial. Allergy2021;76(6):1789-99. [DOI: 10.1111/all.14670]">APeX‐J</a>; <a href="./references#CD013403-bbs2-0004" title="BanerjiA , BusseP , ShennakM , LumryW , Davis‑LortonM , WednerHJ , et al. Inhibiting plasma kallikrein for hereditary angioedema prophylaxis. New England Journal of Medicine2017;376(8):717-28. BanerjiA , BusseP , ShennakM , LumryW , Davis-LortonM , WednerJ , et al. Interim analysis results of a phase 1b, multiple ascending dose study to evaluate DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein in development for long-term prophylaxis of hereditary angioedema. Allergy2015;70(S101):107. BusseP , BanerjiA , ShennakM , LumryW , Davis-LortonM , WednerH , et al. Dx-2930 in patients with hereditary angioedema: final results of a phase 1b study. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. JacobsJS , BussePJ , BanerjiA , ShennakM , LumryWR , Davis-LortonMA , et al. Relationship between drug exposure and clinical response observed in the phase 1b study of DX-2930 in subjects with hereditary angioedema. Journal of Allergy and Clinical Immunology2016;137(2 Suppl):AB251. LumryW , CicardiM , BusseP , BanerjiA , ShennakM , Davis-LortonM , et al. Attack frequency, C1-INH function, and levels of cleaved kininogen do not influence the clinical response to DX-2930 in patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2015;115(5 Suppl):A31. ">Banerji 2017</a>; <a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a>; <a href="./references#CD013403-bbs2-0012" title="RiedlMA , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , GiannettiBM , et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet2017;390(10102):1595-602. YangWH , LiHH , ChaseC , MoldovanD , Grivcheva-PanovskaV , HarperJR , et al. Recombinant Human C1 Inhibitor (rHC1INH) Is efficacious and well tolerated as prophylaxis for prevention of hereditary angioedema (HAE) attacks: a randomized, phase 2 trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB231. ">NCT02247739</a>; <a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a>; <a href="./references#CD013403-bbs2-0015" title="FarkasH , Martinez-SaguerI , YangWH , JohnstonD , TangT , VardiM , et al. Reduction of attack severity with fixed-dose subcutaneous (SC) C1 inhibitor liquid in hereditary angioedema patients: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):720-1. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Allergy2018;73(Suppl 105):287. LumryW , BernsteinJA , JacobsJ , YangWH , MoldovanD , RiedlMA , et al. Fixed-dose subcutaneous (SC) C1 inhibitor liquid for prophylactic treatment of hereditary angioedema attacks: results from the phase 3 SAHARA study. Swiss Medical Weekly2018;148(Suppl 231):26S-7S. LumryWR , Martinez-SaguerI , YangWH , BernsteinJA , JacobsJ , MoldovanD , et al. Fixed-dose subcutaneous C1-inhibitor liquid for prophylactic treatment of C1-INH-HAE: SAHARA randomized study. Journal of Allergy and Clinical Immunology. In Practice2019;7(5):1610-18.e4. ">SAHARA</a>) (<a href="#CD013403-fig-0010">Figure 10</a>). None of the drugs tested in these trials caused a clear increase in the risk of adverse events (<a href="./references#CD013403-fig-0043" title="">Analysis 7.1</a>). Of the four studies that compared different doses of the same drug, none reported clear differences between doses (RR 1.02, 95% CI 0.96 to 1.09; 4 studies, 333 participants; <a href="./references#CD013403-fig-0044" title="">Analysis 7.2</a>) (<a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>; <a href="./references#CD013403-bbs2-0006" title="BernsteinJA , SchwartzL , YangW , BakerJ , AndersonJ , FarkasH , et al. Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2020;125(3):334-40. ChristiansenS , LiH , ChiaoJ , JacobsI . Comparison of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1-INH [SC]) for the prophylactic treatment of hereditary angioedema (HAE): efficacy results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. CraigT , LonghurstH , CicardiM , ZurawB . Safety and efficacy of long-term subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Annals of Allergy, Asthma &amp; Immunology2018;121(Suppl 5):S34. CraigT , ZurawB , LonghurstH , CicardiM , BorkK , GrattanC , et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):1793-802.e2. KatelarisC , PrustyS . Efficacy and safety of subcutaneous C1-inhibitor in Australian patients with hereditary angioedema. Internal Medicine Journal2019;49(Suppl S4):27. LiH , ChiaoJ , JacobsI . Comparison of the safety profiles of 40 IU/kg and 60 IU/kg doses of subcutaneous C1-esterase inhibitor (C1- INH [SC]) in the prophylactic treatment of hereditary angioedema (HAE): results from a phase 3 trial. Allergy and Asthma Proceedings2017;38(5):397. LiHH , CraigTJ , LonghurstH , CicardiM , FeuersengerH , PragstI , et al. Long-term safety of subcutaneous C1-inhibitor in the prophylactic treatment of hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(Suppl 2):AB39. LiHH , FeuersengerH , ChiaoJ , MachnigT , JacobsI . Long-term treatment experience with subcutaneous C1-esterase inhibitor for the prevention of HAE attacks: 2-year efficacy results from the US compact open-label extension study. Allergy and Asthma Proceedings2018;39(5):401. LonghurstH , CicardiM , ZurawB , CraigT , CaballeroT , FarkasH , et al. Subcutaneous C1-INH (SC) preparation (CSL830) in the prevention of hereditary angioedema (HAE) attacks: first findings from the COMPACT extension study. Allergy2017;72(Suppl 103):100-1. LumryWR , ZurawB , CicardiM , CraigT , AndersonJ , BanerjiA , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. Orphanet Journal of Rare Diseases2021;16(1):86. ZurawB , CraigT , CicardiM , LonghurstH , FeuersengerH , PrustyS , KatelarisC . Long-term efficacy of subcutaneous C1-inhibitor in patients with hereditary angioedema and very high attack burden. Internal Medicine Journal2019;49(Suppl S4):27. ">COMPACT extension</a>; <a href="./references#CD013403-bbs2-0010" title="LumryWR , LiHH , MagerlM , MaurerM , BernsteinJA , RiedlMA , et al. Pharmacokinetics of subcutaneous C1 esterase inhibitor (human) with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB192. ReshefA , RiedlM , PanovskaVG , MoldovanD , BakerJ , YangWH , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. World Allergy Organization Journal2017;10(Suppl 1):A106. RiedlM , Grivcheva-PanovskaV , MoldovanD , BakerJ , YangWH , ReshefA , et al. Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks. Allergy and Asthma Proceedings2017;38(3):237. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BaM , et al. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema. Allergy and Asthma Proceedings2016;37(6):489-500. WellerK , MaurerM , FridmanM , SupinaD , SchranzJ , MagerlM . Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. Allergy and Asthma Proceedings2017;38(2):143-51. ">NCT01756157</a>; <a href="./references#CD013403-bbs2-0011" title="Aygören-PürsünE , JacobsonK , MoldovanD , ChristensenJ , vanLeerbergheA , WangY , et al. Safety and efficacy of a C1 inhibitor for the prevention of hereditary angioedema attacks in children: interim results of a phase 3 study. Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):O-14. Aygören-PürsünE , SoteresDF , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema. Pediatric Allergy and Immunology2019;30(5):553-61. FarkasH , Aygoren-PursunE , Martinez-SaguerI , KesselA , HaoJ , LuP , et al. The use of a C1 esterase inhibitor concentrate to manage hereditary angioedema attacks in children. Allergy2017;72(Suppl 103):101. JacobsonK , SoteresD , Nieto-MartinezS , MoldovanD , Martinez-SaguerI , VardiM , et al. C1 inhibitor administration in pediatric patients with hereditary angioedema: patient compliance with intravenous therapy. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. Martinez-SaguerI , SoteresD , vanLeerbergheA , HerreraEM , DevercelliG , VardiM , et al. Improved health-related quality of life in pediatric patients with hereditary angioedema (HAE): a phase 3 study of C1 inhibitor for attack prevention. Allergy2018;73(Suppl 105):718. SoteresDF , Aygoren-PursunE , Nieto-MartinezSA , ChristensenJ , JacobsonKW , MoldovanD , et al. Safety, efficacy, and pharmacokinetics of intravenous C1 esterase inhibitor (human) prophylaxis in children with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. ">NCT02052141</a>). </p> <div class="figure" id="CD013403-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Risk of any adverse event compared with placebo by drug." data-id="CD013403-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-10.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of any adverse event compared with placebo by drug.</p> </div> </div> </div> </section> <section id="CD013403-sec-0066"> <h5 class="title">Publication bias</h5> <p>We assessed publication bias using a funnel plot analysis for outcomes with at least 10 included study arms (<a href="#CD013403-fig-0011">Figure 11</a>; <a href="#CD013403-fig-0012">Figure 12</a>). Visual inspection of the funnel plot of studies reporting on the number of HAE attacks per week suggested that it is possible that some studies of lower methodological quality with negative results may be missing (<a href="#CD013403-fig-0011">Figure 11</a>). This slight skewing of the funnel plot was not evident in the plot of adverse events (<a href="#CD013403-fig-0012">Figure 12</a>). </p> <div class="figure" id="CD013403-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Change in number of hereditary angioedema attacks per week by drug (approved doses only)." data-id="CD013403-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-11.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Change in number of hereditary angioedema attacks per week by drug (approved doses only). </p> </div> </div> </div> <div class="figure" id="CD013403-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Risk of any adverse event compared with placebo by drug." data-id="CD013403-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-12.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of any adverse event compared with placebo by drug.</p> </div> </div> </div> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013403-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013403-sec-0067"></div> <section id="CD013403-sec-0068"> <h3 class="title" id="CD013403-sec-0068">Summary of main results</h3> <section id="CD013403-sec-0069"> <h4 class="title">Risk of hereditary angioedema attacks</h4> <p>For people with HAE, the number of attacks they experience is the most important outcome. Most studies reported the risk of HAE attacks during prophylactic treatment as the primary trial outcome. At doses approved by the US Food and Drug Administration, all drugs except avoralstat reduced the incidence of breakthrough attacks (berotralstat was borderline significant, P = 0.05) (<a href="./references#CD013403-fig-0014" title="">Analysis 1.2</a>). C1‐INH(SC) reduced attack rates from 81% to 23% and danazol from 94% to 2%. In contrast, taking berotralstat only reduced the risk from 91% to 57%. This result should be confirmed in other, preferably head‐to‐head studies. Nevertheless, the current findings suggest that berotralstat is only moderately effective in preventing HAE attacks when compared to placebo. </p> <p>Similarly, when examined as a change in the mean number of HAE attacks per week, avoralstat showed no clear difference compared with placebo, whereas all other drugs reduced the number of attacks (<a href="./references#CD013403-fig-0020" title="">Analysis 2.2</a>). However, there were differences between subgroups. For example, the MD between berotralstat and placebo was smaller than the difference between C1‐INH(SC) and placebo, and rhC1‐INH versus placebo. Similarly, the difference between lanadelumab and placebo was smaller than the difference between C1‐INH(SC) and placebo, and rhC1‐INH versus placebo. However, our confidence in this analysis was limited by the small number of studies, with very few participants in each study. </p> <p>The study comparing two doses of a single drug (C1‐INH) with one another found no clear differences between the doses (<a href="./references#CD013403-fig-0018" title="">Analysis 1.6</a>). </p> </section> <section id="CD013403-sec-0070"> <h4 class="title">Quality of life</h4> <p>Another important outcome for people with HAE is quality of life. When measured using the validated AE‐QoL Questionnaire, both avoralstat and berotralstat lowered the AE‐QoL score compared with placebo (<a href="./references#CD013403-fig-0029" title="">Analysis 4.1</a>). Importantly, the MCID for the AE‐QoL is −6 points; therefore, avoralstat (MD 6.78 points) and berotralstat (MD −15.28 points) were effective in improving quality of life to a clinically significant degree. </p> <p>Interestingly, avoralstat did not reduce the number of attacks in the <a href="./references#CD013403-bbs2-0013" title="Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Efficacy correlates with plasma levels in OPuS-1, a proof-of-concept study of oral kallikrein inhibitor BCX4161 as a prophylaxis against attacks of hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2015;135(Suppl 1):AB192. Aygören-PürsünE , MagerlM , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. Prophylaxis of hereditary angioedema attacks: a randomized trial of oral plasma kallikrein inhibition with avoralstat. Journal of Allergy and Clinical Immunology2016;138(3):934-6.e5. MagerlM , Aygören-PürsünE , GraffJ , Martinez-SaguerI , KreuzW , LonghurstH , et al. BCX4161, an oral kallikrein inhibitor, showed significant benefits on reducing disease burden and improving quality of life in subjects with hereditary angioedema in the OPuS-1 study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. MagerlM , RaeW , Aygoren-PursunE , BygumA , PanovskaVG , SteinerUC , et al. Prophylactic therapy with BCX7353 improves anxiety and stress in hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) patients. Allergy2018;73(Suppl 105):414. ">OPuS‐1</a> and <a href="./references#CD013403-bbs2-0014" title="RiedlMA , Aygören-PürsünE , BakerJ , FarkasH , AndersonJ , BernsteinJA , et al. Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy2018;73(9):1871-80. ">OPuS‐2</a> studies, but nevertheless improved quality of life (<a href="./references#CD013403-fig-0032" title="">Analysis 4.4</a>). Although the study authors described this as "intriguing" they failed to ask the study participants to explain the basis for the perceived improvement in the quality of life. </p> </section> <section id="CD013403-sec-0071"> <h4 class="title">Severity of breakthrough attacks</h4> <p>Studies reported the reduction in severity of breakthrough attacks in two different ways. Some studies measured the severity of breakthrough attacks using a continuous scale (<a href="./references#CD013403-fig-0034" title="">Analysis 5.1</a>). The reported data show that C1‐INH(SC) was effective in reducing the mean severity of attacks compared with placebo. When measured on a 0 to 3 scale, (representing no symptoms ('0'); mild symptoms ('1'); moderate symptoms ('2'); or severe symptoms ('3')), C1‐INH(SC) reduced the severity of attacks compared with placebo (40 IU/kg twice per week: by 0.26, 60 IU/kg twice per week: by 0.30: 1000 IU twice per week: by 0.60 points). Unfortunately, no other studies reported on the change in severity using a continuous scale, so comparison between different drugs was not possible. </p> <p>Other studies reported breakthrough attack severity as the percentage of people experiencing no symptoms, or a mild, moderate, or severe attack, compared with placebo (<a href="./references#CD013403-fig-0035" title="">Analysis 5.2</a>; <a href="./references#CD013403-fig-0036" title="">Analysis 5.3</a>; <a href="./references#CD013403-fig-0037" title="">Analysis 5.4</a>; <a href="./references#CD013403-fig-0038" title="">Analysis 5.5</a>). Compared with placebo, C1‐INH reduced the risk of a severe breakthrough attack by 73%. The overall RR for all C1‐INH drugs combined, compared with placebo, was 0.27 (95% CI 0.14 to 0.52); lanadelumab reduced the risk of a severe breakthrough attack to a similar degree (RR 0.22, 95% CI 0.05 to 0.88). </p> <p>The risk of having no symptoms also supported the use of HAE treatments. C1‐INH increased the risk of having no symptoms (RR 4.37, 95% CI 2.24 to 8.55). The RR for lanadelumab versus placebo was much higher, but based on a single, small study (RR 18.22, 95% CI 2.51 to 132.15). The test for subgroup differences showed no clear differences between the subgroups. </p> </section> <section id="CD013403-sec-0072"> <h4 class="title">Disability</h4> <p>Studies reported change in disability for three drugs (berotralstat, C1‐INH‐nf, and lanadelumab). </p> <p>Using the SF‐36 Physical Functioning component summary as a measure of disability, C1‐INH‐nf improved disability compared with placebo in one small study (MD 6.80 points, 95% CI 1.36 to 12.24). No MCID has been established for this subscale in people with HAE, but one study in children (<a href="./references#CD013403-bbs2-0060" title="BrigdenA , ParslowRM , GauntD , CollinSM , JonesA , CrawleyE . Defining the minimally clinically important difference of the SF-36 physical function subscale for paediatric CFS/ME: triangulation using three different methods. Health and Quality of Life Outcomes2018;16:202.">Brigden 2018</a>) and one study in people with asthma (<a href="./references#CD013403-bbs2-0096" title="WyrwichKW , TierneyWM , BabuAN , KroenkeK , WolinskyFD . A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. Health Services Research2005;40(2):577-92.">Wyrwich 2005</a>) found the MCID in these populations to be −10 points. If this were true also for HAE, then this difference would be statistically, but not clinically significant. The SMD for this analysis was −0.84, which corresponds to a 'large' effect, according to <a href="./references#CD013403-bbs2-0064" title="CohenJ . Statistical power analysis for the behavioral sciences. 2nd edition. New York (NY): Taylor &amp; Francis, 1988. [DOI: 10.4324/9780203771587] [ISBN: 9780203771587]">Cohen 1988</a>. Therefore, it is likely that this difference is clinically relevant. </p> <p>Two small studies comparing berotralstat with placebo used the Physical Functioning component of the AE‐QoL as a measure of disability. Meta‐analysis of the two studies demonstrated a reduction in disability of 22.5 points (95% CI −34.91 to −10.08). There is currently no established MCID for the subscales of the AE‐QoL. However, the SMD for this comparison was −1.01, which is a 'large' difference according to <a href="./references#CD013403-bbs2-0064" title="CohenJ . Statistical power analysis for the behavioral sciences. 2nd edition. New York (NY): Taylor &amp; Francis, 1988. [DOI: 10.4324/9780203771587] [ISBN: 9780203771587]">Cohen 1988</a>. Therefore, it is likely that this difference is also clinically relevant. </p> <p>The <a href="./references#CD013403-bbs2-0008" title="BanerjiA , RiedlM , BernsteinJ , CicardiM , LonghurstH , ZurawB , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S5. BanerjiA , RiedlM , ZurawB , LumryW , LuP , HaoJ , et al. Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S5. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA2018;320(20):2108-21. BanerjiA , RiedlMA , BernsteinJA , CicardiM , LonghurstHJ , ZurawBL , et al. Lanadelumab for prevention of attacks in hereditary angioedema: results from the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S-9S. BernsteinJA , BanerjiA , SchranzJ , NurseC , RiedlM , LuP . Lanadelumab reduces high morbidity attacks in patients with hereditary angioedema (HAE): results from the phase 3 HELP study. Allergy2018;73(Suppl 105):288-89. BussePJ , TachdjianR , Martinez-SaguerI , LuP , NurseC , Aygoren-PursunE . Efficacy and safety of lanadelumab for prophylactic treatment in adolescents with hereditary angioedema (HAE). Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB43. CicardiM , ShennakM , Zaragoza-UrdazRH , WangY , LuP . Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study. Allergy2018;73(Suppl 105):722. CraigT , Zaragoza-UrdasR , AndersonJ , LiH , PaesK , RenH , JuethnerS . Response to lanadelumab is not affected by race and ethnicity: findings from phase 3 studies. Journal of Allergy and Clinical Immunology2021;147(2 Suppl):AB21. GagnonR , CicardiM , ShennakM , Zaragoza-UrdazR , MarierJF , LuP , et al. Lanadelumab Inhibition of plasma kallikrein activity for effective HAE prophylaxis. Allergy, Asthma, and Clinical Immunology2019;15(Suppl 1):A63. HebertJ , BanerjiA , BernsteinJA , BussePJ , CicardiM , Davis-LortonM , et al. Efficacy and safety of lanadelumab for prevention of hereditary angioedema attacks: results from the phase 3 HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A66. JacobsJS , BernsteinJ , Davis-LortonM , LiHH , SoteresDF , NurseC , et al. Increased response to higher dose lanadelumab in hereditary angioedema patients: exploratory findings from the HELP and HELP OLE studies. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. JainG , SussmanG , LumryWR , LuP , LewisH , MaurerM . Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):10. JohnstonD , BanerjiA , RiedlM , ZurawB , LumryW , BernsteinJ , et al. Lanadelumab safety and immunogenicity: results from the phase 3 HELP study. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S36. JohnstonDT , AndersonJT , SchranzJ , NurseC , CicardiM . Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):1524-5. LonghurstH , LumryW , WellerK , MagerlM , LuP , JainG , et al. Lanadelumab improves health-related quality of life in patients with hereditary angioedema (HAE): findings from the HELP study. Clinical and Experimental Allergy2018;48(11):OP.019. LumryWR , WellerK , MagerlM , BanerjiA , LonghurstHJ , RiedlMA , et al. Impact of lanadelumab on health-related quality of life inpatients with hereditary angioedema in the HELP study. Allergy2021;76(4):1188-98. LumryWR , WellerK , MagerlM , LuP , JainG , LewisH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Swiss Medical Weekly2018;148(Suppl 231):28S. LumryWR , WellerK , MagerlM , SchranzJ , JainG , DollH , et al. Lanadelumab markedly improves health-related quality of life in hereditary angioedema patients in the HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. MaurerM , Davis-LortonM , SchranzJ , HaoJ , BussePJ . High responder rates in lanadelumab-treated patients in the phase 3 HELP study. Allergy2018;73(Suppl 105):289-90. MaurerM , GiererS , HébertJ , HaoJ , LuP , BanerjiA . Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Allergy2018;73(Suppl 105):289. MaurerM , GiererS , HebertJ , HaoJ , LuP , BruelleJ , et al. Lanadelumab is highly efficacious at steady-state in hereditary angioedema (HAE): results of the phase 3 HELP study. Swiss Medical Weekly2018;148(Suppl 231):36S. RiedlMA , MaurerM , BernsteinJA , BanerjiA , LonghurstHJ , LiHH , et al. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy2020;75(11):2879-87. RiedlMA , TachdjianR , SchranzJ , NurseC , BernsteinJA . Consistent lanadelumab treatment effect in patients with hereditary angioedema (HAE) regardless of baseline attack frequency in the phase 3 HELP study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB47. SchmaierAH , BauerKA , CicardiM , HebertJ , JohnstonDT , BussePJ , et al. Effect of lanadelumab on coagulation parameters in patients with hereditary angioedema: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB41. SextonDJ , BrownNJ , LumryWR , GowerRG , HaoJ , LuP , et al. Lanadelumab and cardiovascular risk: findings from the phase 3 HELP study. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB45. WangY , MarierJF , KassirN , GosselinNH , MartinP . Exposure-response analyses of lanadelumab in patients with hereditary angioedema. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB40. YangWH , AndersonJT , BusseP , CicardiM , Davis-LortonM , JohnstonDT , et al. Efficacy of lanadelumab in the phase 3 HELP study: exploratory analyses based on prior disease activity and prior use of C1-INH long term prophylaxis therapy. Allergy, Asthma and Clinical Immunology2019;15(Suppl 1):A64. ZanichelliA , HebertJ , SoteresD , HaoJ , LuP , BusseP . Efficacy of lanadelumab in patients with HAE is independent of body mass index: findings from the HELP study. Allergy2018;73(Suppl 105):722-3. ">HELP</a> trial revealed a reduction in physical impairment of 30.55 points in the AE‐QoL Physical Functioning subscale with lanadelumab versus placebo (95% CI −37.55 to −23.55; 1 study, 64 participants; <a href="./references#CD013403-fig-0041" title="">Analysis 6.2</a>). The SMD for this comparison was −1.38, which is a 'large' difference according to <a href="./references#CD013403-bbs2-0064" title="CohenJ . Statistical power analysis for the behavioral sciences. 2nd edition. New York (NY): Taylor &amp; Francis, 1988. [DOI: 10.4324/9780203771587] [ISBN: 9780203771587]">Cohen 1988</a>. Therefore, it is likely that this difference is clinically relevant. </p> </section> <section id="CD013403-sec-0073"> <h4 class="title">Adverse events</h4> <p>None of the studies reported a clear difference in serious adverse events (<a href="./references#CD013403-fig-0027" title="">Analysis 3.1</a>) or any adverse event (<a href="./references#CD013403-fig-0043" title="">Analysis 7.1</a>). Therefore, all drugs that were investigated in this review appear to be safe compared with placebo. There were also no clear differences in serious adverse events (<a href="./references#CD013403-fig-0028" title="">Analysis 3.2</a>) or any adverse event (<a href="./references#CD013403-fig-0044" title="">Analysis 7.2</a>) in trials comparing different doses of the same drug. </p> <p>As there were no deaths in any of the studies, we could not perform analyses with mortality as an outcome. </p> </section> </section> <section id="CD013403-sec-0074"> <h3 class="title" id="CD013403-sec-0074">Overall completeness and applicability of evidence</h3> <p>Originally, we had planned a several subgroup analyses. For example, we hoped to analyse data by age, sex, type of HAE, and BMI of the participants, by the region in which the work was done, by route of administration, etc. (<a href="./references#CD013403-bbs2-0100" title="BeardN , FreseM , MereP , KatelarisC , MillsK . Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database of Systematic Reviews2019, Issue 8. Art. No: CD013403. [DOI: 10.1002/14651858.CD013403]">Beard 2019</a>). However, only a small number of studies met the inclusion criteria. In addition, the small number of people with HAE means that even in multicentre, multinational trials, no single study enroled more than 150 participants. In fact, the studies that focussed on children often had to pool studies to increase numbers for a statistically meaningful analysis. </p> <p>For this reason, it is difficult to know how applicable the results of this analysis are for an individual. We cannot be sure if the drugs are more or less effective in men versus women, children versus adults and Type I versus Type II HAE. Furthermore, although we carried out a thorough search, we did not find any studies in people with Type III HAE. </p> <p>In addition, all the studies on people with HAE were performed in Western countries. HAE is present in countries worldwide. Given that the available evidence did not allow us to determine if racial, social or other factors alter our results, we must state this as a limitation of the data. </p> <p>The lack of head‐to‐head trials for different drugs is also a limitation of our study. Although we found that some studies tested different doses of the same drug, not a single identified trial tested two different drugs in the same population. Therefore, we cannot state with confidence that one drug is superior to another. However, indirect evidence (i.e. comparing the effect sizes or RRs between drugs and placebo) gave some indications that C1‐INH may be more effective than both lanadelumab and berotralstat in reducing the number of breakthrough HAE attacks per week. Furthermore, the two single studies that compared C1‐INH(SC) (<a href="./references#CD013403-bbs2-0005" title="AndersonJ , KrishnarajahG , CraigT , LumryW , SupinaD , FeuersengerH , et al. Use of rescue medication in hereditary angioedema attacks and its relation to attack severity. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl 1):S40. ChristiansenS , ZurawB , FeuersengerH , PragstI , PawaskarD . C1-Esterase inhibitor (C1-INH) functional activity of subcutaneous C1-INH for the prevention of hereditary angioedema (HAE) attacks: pharmacokinetic comparison in adolescent and adult patients. Allergy2018;73(Suppl 105):613-4. CicardiM , ZurawB , CraigT , LonghurstH , FeuersengerH , JacobsI , et al. Onset of effect of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks: findings from the phase III compact study. Allergy2018;73(Suppl 105):615-6. CraigT , LumryW , CicardiM , ZurawB , BernsteinJA , AndersonJ , et al. Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. Journal of Allergy and Clinical Immunology. In Practice2019;7(6):2035-8. CraigT , ZurawB , CicardiM , LonghurstH , ChiaoJ , FeuersengerH , et al. Prevention of hereditary angioedema (HAE) attacks by anatomical location with subcutaneous C1-esterase inhibitor (C1-INH [SC]) treatment: results from the phase III COMPACT study. Allergy2018;73(Suppl 105):615. CraigT , ZurawB , LumryW , BernsteinJ , CicardiM , AndersonJ , et al. Preventive effect of subcutaneous C1 inhibitor in patients with very frequent attacks of hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2017;119(Suppl 5):S4. GowerR , LiHH , LevyDS , JacobsI . Response to subcutaneous C1-esterase inhibitor (C1-INH [SC]), a prophylactic treatment for adolescents and adults with hereditary angioedema: results from the phase 3 compact trial. Journal of Adolescent Health2018;62(2 Suppl):S5-6. LevyD , CaballeroT , HussainI , ReshefA , AndersonJ , BakerJ , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Pediatric Allergy, Immunology, and Pulmonology2020;33(3):136-41. LevyDS , ChiaoJ , FeuersengerH , CraigT , LonghurstHJ , CicardiM , et al. Prevention of attacks of hereditary angioedema (HAE) with subcutaneous C1-esterase inhibitor (C1-INH [SC]) by anatomical location: results from the phase III COMPACT study (NCT01912456). Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LevyDS , CraigT , ZurawB , CicardiM , LonghurstH , FeuersengerH , et al. Prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) reduces symptom days and severity of symptoms in patients with hereditary angioedema (HAE): results from the COMPACT study. Allergy2018;73(Suppl 105):611-2. LiHH , MycroftS , ChristiansenS , WoodDN , FeuersengerH , PawaskarD , et al. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: safety findings from the COMPACT trial. Allergy and Asthma Proceedings2018;39(5):365-70. LiHH , RiedlMA , CraigT , LonghurstHJ , CicardiM , ZurawBL , et al. Initiation of prophylactic treatment with subcutaneous C1-esterase inhibitor (C1-INH [SC]) for prevention of hereditary angioedema (HAE) attacks and onset of effect: findings from the phase III COMPACT study. Journal of Allergy and Clinical Immunology2018;141(2 Suppl):AB45. LiHH , ZurawB , LonghurstHJ , CicardiM , BorkK , BakerJ , et al. Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo‑controlled randomized study. Allergy, Asthma and Clinical Immunology2019;15:49. LonghurstH , CicardiM , CraigT , BorkK , GrattanC , BakerJ , et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. New England Journal of Medicine2017;376(12):1131-40. LonghurstHJ , LiHH , RiedlMA , CraigTJ , ReshefA , FarkasH , et al. Subcutaneous C1-esterase inhibitor [C1-INH(SC)] to prevent hereditary angioedema (HAE) attacks: subject and investigator assessments from the compact trial. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB234. LumryW , BernsteinJ , CicardiM , ZurawB , CraigT , CaballeroT , et al. Subcutaneous C1 inhibitor prophylaxis substantially reduces the need for rescue medications in the compact study. Annals of Allergy, Asthma &amp; Immunology2017;119(5 Suppl):S39. LumryW , CraigTJ , FarkasH , FeuersengerH . Health-related quality of life (HRQoL) and changes in work productivity measures with subcutaneous C1-inhibitor [C1-INH(SC)] for the prevention of hereditary angioedema (HAE) attacks: findings from the compact study. Journal of Allergy and Clinical Immunology2017;139(2 Suppl):AB233. LumryWR , CraigT , CicardiM , ZurawBL , LonghurstH , FarkasH , et al. Can routine prophylactic subcutaneous C1-inhibitor [C1-INH(SC)] alleviate psychological and physical disabilities caused by HAE? Findings from the COMPACT study (NCT01912456). Allergy, Asthma and Clinical Immunology2017;13(Suppl 2):29. LumryWR , CraigT , ZurawB , LonghurstH , BakerJ , LiHH , et al. Health-related quality of life with subcutaneous C1-Inhibitor for prevention of attacks of hereditary angioedema. Journal of Allergy and Clinical Immunology. In Practice2018;6(5):1733-41. LumryWR , CraigTJ , MagerlMA , FarkasH , LawoJP , ChiaoJ , et al. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks. Journal of Allergy and Clinical Immunology2019;143(2 Suppl):AB38. MagerlM , BernsteinJA , BanerjiA , LiHH , LumryWR , MaurerM , et al. Response to subcutaneous human C1-inhibitor for the prevention of angioedema attacks in patients with hereditary angioedema: subgroups based on prior intravenous C1-inhibitor use. Allergy2015;70(S101):60. ManningM , CaballeroT , HussainI , FeuersengerH , ChiaoJ , JacobsI , et al. Long-term efficacy of subcutaneous C1 inhibitor in pediatric patients with hereditary angioedema. Annals of Allergy, Asthma &amp; Immunology2018;121(5 Suppl):S31-2. PatelAS , WatsonDJ , FeuersengerH , PragstI , MycroftS , CraigT . On-demand vs prophylactic subcutaneous C1-esterase inhibitor for the management of hereditary angioedema: a benefit-risk assessment of the COMPACT study data. Allergy2018;73(Suppl 105):614-5. RiedlMA , JacobsJ , LiHH , LevyDS , ChiaoJ , FeuersengerH , et al. Efficacy of prophylaxis with subcutaneous C1-esterase inhibitor (C1-INH [SC]) in female patients with hereditary angioedema: subgroup analysis from the COMPACT study. Allergy2018;73(Suppl 105):614. RiedlMA , LumryWR , LiHH , BanerjiA , BernsteinJA , BasM , et al. Subcutaneous human C1-inhibitor with recombinant human hyaluronidase for the prevention of angioedema attacks in patients with hereditary angioedema: results of a randomized, double-blind, dose-ranging, crossover study. Journal of Allergy and Clinical Immunology2015;135(2 Suppl):AB278. TarziM , CicardiM , ZurawB , CraigT , LonghurstH , CaballeroT , et al. Prevention of hereditary angioedema (HAE) attacks with subcutaneous C1-INH (SC) preparation of CSL830 in the COMPACT study: effects on severity and attack location. Allergy2017;72(Suppl 103):597. WellerK , MaurerM , MagerlM , FridmanM , SupinaD , SchranzJ . Subcutaneous human C1-inhibitor (C1-INH) with recombinant human hyaluronidase (rHuPH20) for the prevention of angioedema attacks in patients with hereditary angioedema (HAE): health-related quality of life (HRQoL) results from a randomized, double-blind, dose-ranging, crossover study. Allergy2015;70(S101):253. ">COMPACT</a>) and danazol (<a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a>) with placebo suggest that both drugs may be superior to berotralstat in preventing the risk of having a breakthrough attack. However, as stated above, the indirect comparisons are hypothesis‐generating only, and should be tested with network meta‐analysis or head‐to‐head trials, or both. </p> <p>Tranexamic acid and danazol are two older drugs that are taken orally. They have long been used for the prophylaxis of HAE attacks. However, the 2020 Position Paper of the Australasian Society of Clinical Immunology and Allergy stated that the drugs have "significant problems, lack of efficacy or side effects" (<a href="./references#CD013403-bbs2-0056" title="Australasian Society of Clinical Immunology and Allergy. Hereditary angioedema (HAE) position paper. allergy.org.au/images/docs/ASCIA_HP_Position_Paper_HAE_2020_Aug_Update.pdf (accessed 13 May 2021).">ASCIA 2020</a>). However, we identified only one randomised controlled trial using danazol (<a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a>), and none using tranexamic acid. Therefore, we believe there to be no high‐certainty evidence to suggest that these drugs are ineffective or unsafe. In fact, a single, double‐blind, controlled trial comparing danazol with placebo found a very large reduction in the risk of HAE attacks. However, this small trial (nine participants undertaking 47 placebo courses and 44 danazol courses) has never been replicated, used the highest dose approved by the US FDA, and included no safety data (<a href="./references#CD013403-bbs2-0007" title="GelfandJA , SherinsRJ , AllingDW , FrankMM . Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. New England Journal of Medicine1976;295(26):1444-8. ">Gelfand 1976</a>). One non‐randomised study looked at adverse events resulting from long‐term prophylaxis with the attenuated androgens, danazol and stanozolol, and compared these adverse events with rates in people with HAE who had never received either drug (<a href="./references#CD013403-bbs2-0032" title="CicardiM , CastelliR , ZingaleLC , AgostoniA . Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. Journal of Allergy and Clinical Immunology1997;2:194-6. ">Cicardi 1997</a>). The participants had been taking the attenuated androgens for a median of 125.5 months (range: 22 to 273 months). <a href="./references#CD013403-bbs2-0063" title="CicardiM , CastelliR , ZingaleLC , AgostoniA . Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. Journal of Allergy and Clinical Immunology1997;99:194-6.">Cicardi 1997</a> found a dose‐related incidence of menstrual irregularities in 50% of premenopausal women, and a dose‐related increase in bodyweight in 28% of all participants. Hypertension was also more prevalent in people taking danazol than untreated controls. A conference abstract also described a case‐control study comparing women taking danazol versus untreated women (<a href="./references#CD013403-bbs2-0051" title="ZotterZ , CzallerI , CsukaD , SzaboE , KohalmiKV , VargaL , et al. Adverse effects of danazol prophylaxis in female patients with hereditary angioedema due to C1-INH deficiency (HAE-C1-INH). Allergy: European Journal of Allergy and Clinical Immunology2013;97:430. ">Zotter 2013</a>). They found that in the 31 participants taking danazol for HAE, hirsutism was experienced by 13 women, weight gain by 12, menstrual disturbances by seven, and diaphoresis by seven. Despite this, the women rated their satisfaction with danazol treatment at 8.47 out of 10. There were no adverse changes for total cholesterol, triglycerides, low‐density lipoprotein, very low‐density lipoprotein, lipoprotein(a) and liver function. However, the study design (cohort study) precludes assigning causation to any of these outcomes. Furthermore, the participants in <a href="./references#CD013403-bbs2-0032" title="CicardiM , CastelliR , ZingaleLC , AgostoniA . Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. Journal of Allergy and Clinical Immunology1997;2:194-6. ">Cicardi 1997</a> who received danazol experienced two or fewer breakthrough attacks per year; so, for some patients, the reduction in attacks may be a reasonable trade‐off for increased adverse effects, particularly in men or postmenopausal women, and in people with low bodyweight and hypotension. Indeed, <a href="./references#CD013403-bbs2-0051" title="ZotterZ , CzallerI , CsukaD , SzaboE , KohalmiKV , VargaL , et al. Adverse effects of danazol prophylaxis in female patients with hereditary angioedema due to C1-INH deficiency (HAE-C1-INH). Allergy: European Journal of Allergy and Clinical Immunology2013;97:430. ">Zotter 2013</a> stated that the adverse events had not led to the discontinuation of danazol therapy in any participant. </p> </section> <section id="CD013403-sec-0075"> <h3 class="title" id="CD013403-sec-0075">Quality of the evidence</h3> <p>Most of the studies were of good methodological quality. The majority of trials had published a protocol prior to the start of the trial, were double‐blind, placebo‐controlled and reported all relevant results. The rarity of the disease means that the trials were relatively small, and there were rarely multiple trials for a drug. This made it impossible to assign comparative efficacies to drugs to treat HAE. </p> <p>Almost all studies were funded by pharmaceutical companies. Although this does not necessarily mean that the results are biased in favour of the drug, we would have more confidence in the results if studies with corroborating results were published that had been funded by organisations without a financial interest in the outcome. We did not downgrade the certainty of the evidence for this reason, as the authors of the studies carried out clinical trials for several companies and several HAE drugs. Therefore, we believe the likelihood of bias for one drug, but not another, is unlikely. </p> <p>Furthermore, most studies in this analysis did not report their method of randomisation or whether allocation was concealed. This leaves open the possibility that enrolment staff could anticipate the allocation of a particular patient, which can lead to biased outcomes. Similarly, around half of the studies had unclear blinding of outcome assessors, which could also have compromised the outcomes. We decided not to downgrade the certainty of evidence for these reasons, because several studies were cross‐over in design, which overcomes the potential of allocation bias, and the studies were performed at centralised facilities that use standardised methods. </p> <p>The summary of findings tables reveal a generally low degree of certainty around our results (<a href="./full#CD013403-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD013403-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD013403-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD013403-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD013403-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD013403-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD013403-tbl-0007">summary of findings Table 7</a>). The studies were downgraded mostly due to imprecision (few studies, small study sizes and few events). </p> <p>We found moderate‐certainty evidence that avoralstat does not reduce the risk of HAE attacks compared with placebo, and low‐certainty evidence it does not reduce the number of attacks compared with placebo, but also moderate‐certainty evidence that it improves quality of life. We found low‐certainty evidence that avoralstat does not increase the risk of adverse events, and very‐low certainty evidence that it does not increase the risk of serious adverse events (<a href="./full#CD013403-tbl-0001">summary of findings Table 1</a>). </p> <p>Low‐certainty evidence suggests that berotralstat reduces the risk and number of HAE attacks per week and moderate‐certainty evidence that it increases quality of life. Moderate‐certainty evidence suggests that berotralstat does not increase the risk of adverse events, and low‐certainty evidence suggests that it does not increase the risk of serious adverse events (<a href="./full#CD013403-tbl-0002">summary of findings Table 2</a>). </p> <p>We found low‐certainty evidence that C1‐INH(SC) lowers the risk of HAE attacks and low‐certainty evidence that it does not increase quality of life. We also found moderate‐certainty evidence that C1‐INH(SC) does not increase the risk of adverse events, and very low‐certainty evidence that it does not increase the risk of serious adverse events (<a href="./full#CD013403-tbl-0003">summary of findings Table 3</a>). </p> <p>Low‐certainty evidence suggests that pdC1‐INH reduces the number of HAE attacks per week, and low‐certainty evidence that it does not increase quality of life. We found low‐certainty evidence that pdC1‐INH does not increase the risk of adverse events, and very low‐certainty evidence that it does not increase serious adverse events (<a href="./full#CD013403-tbl-0004">summary of findings Table 4</a>). </p> <p>Very low‐certainty evidence suggests that C1‐INH‐nf reduces the number of HAE attacks per week, increases quality of life, and reduces disability (<a href="./full#CD013403-tbl-0005">summary of findings Table 5</a>). Similarly, very low‐certainty evidence suggests that rhC1‐INH reduces the number of HAE attacks per week (<a href="./full#CD013403-tbl-0006">summary of findings Table 6</a>), and does not increase the risk of serious adverse events, and low‐certainty evidence that it does not increase the risk of adverse events. </p> <p>Finally, low‐certainty evidence suggests that lanadelumab reduces the number of HAE attacks per week and increases quality of life. Low‐certainty evidence suggests that lanadelumab lowers the risk of adverse events, but does not change the risk of serious adverse events (<a href="./full#CD013403-tbl-0007">summary of findings Table 7</a>). </p> </section> <section id="CD013403-sec-0076"> <h3 class="title" id="CD013403-sec-0076">Potential biases in the review process</h3> <p>Given the paucity of studies for our analysis, we made the decision to deviate from our a priori protocol (<a href="./references#CD013403-bbs2-0100" title="BeardN , FreseM , MereP , KatelarisC , MillsK . Interventions for the long-term prevention of hereditary angioedema attacks. Cochrane Database of Systematic Reviews2019, Issue 8. Art. No: CD013403. [DOI: 10.1002/14651858.CD013403]">Beard 2019</a>). We identified several studies that were clearly intended to be prophylaxis trials, but did not meet our inclusion criterion of six weeks in duration. We decided that, on balance, the benefits gained by the additional information by including the studies of a four‐week duration outweighed the risk of bias that this deviation engenders. </p> <p>In order to compensate for a lack of data, we imputed several SDs using the mean SDs of similar studies. We intended to undertake sensitivity analyses removing these studies, but the paucity of information remaining after such removal resulted in meaningless data. </p> </section> <section id="CD013403-sec-0077"> <h3 class="title" id="CD013403-sec-0077">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, there is no other meta‐analysis on this topic. The individual studies found, for the most part, similar results to our meta‐analysis, often because our subgroups contained only one or a very few trials. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013403-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013403-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013403-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013403-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of hereditary angioedema attacks by drug (approved doses only)." data-id="CD013403-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of hereditary angioedema attacks by drug (approved doses only).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Change in number of hereditary angioedema attacks per week by drug (approved doses only)." data-id="CD013403-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Change in number of hereditary angioedema attacks per week by drug (approved doses only). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Risk of serious adverse events compared with placebo by drug." data-id="CD013403-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Risk of serious adverse events compared with placebo by drug.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Change in Angioedema Quality of Life (AE‐QoL) Questionnaire scores." data-id="CD013403-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Change in Angioedema Quality of Life (AE‐QoL) Questionnaire scores.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Change in quality of life (all scales) by drug." data-id="CD013403-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Change in quality of life (all scales) by drug.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Change in disability compared with placebo by drug (approved doses only) (standardised mean difference)." data-id="CD013403-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Change in disability compared with placebo by drug (approved doses only) (standardised mean difference). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Risk of any adverse event compared with placebo by drug." data-id="CD013403-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Risk of any adverse event compared with placebo by drug.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Change in number of hereditary angioedema attacks per week by drug (approved doses only)." data-id="CD013403-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Change in number of hereditary angioedema attacks per week by drug (approved doses only). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-FIG-12" target="_blank"><b></b></a></p> </div><img alt="Risk of any adverse event compared with placebo by drug." data-id="CD013403-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-FIG-12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Risk of any adverse event compared with placebo by drug.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-FIG-12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Risk of hereditary angioedema (HAE) attacks, Outcome 1: Risk of HAE attacks by drug vs placebo" data-id="CD013403-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Risk of hereditary angioedema (HAE) attacks, Outcome 1: Risk of HAE attacks by drug vs placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Risk of hereditary angioedema (HAE) attacks, Outcome 2: Risk of HAE attacks by drug (approved doses only)" data-id="CD013403-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Risk of hereditary angioedema (HAE) attacks, Outcome 2: Risk of HAE attacks by drug (approved doses only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Risk of hereditary angioedema (HAE) attacks, Outcome 3: Risk of HAE attacks by dose (avoralstat)" data-id="CD013403-fig-0015" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Risk of hereditary angioedema (HAE) attacks, Outcome 3: Risk of HAE attacks by dose (avoralstat) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Risk of hereditary angioedema (HAE) attacks, Outcome 4: Risk of HAE attacks by dose (berotralstat)" data-id="CD013403-fig-0016" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Risk of hereditary angioedema (HAE) attacks, Outcome 4: Risk of HAE attacks by dose (berotralstat) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Risk of hereditary angioedema (HAE) attacks, Outcome 5: Risk of HAE attacks by dose (C1‐INH(SC))" data-id="CD013403-fig-0017" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Risk of hereditary angioedema (HAE) attacks, Outcome 5: Risk of HAE attacks by dose (C1‐INH(SC)) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Risk of hereditary angioedema (HAE) attacks, Outcome 6: Risk of HAE attacks (C1‐INH) – head‐to‐head trials" data-id="CD013403-fig-0018" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Risk of hereditary angioedema (HAE) attacks, Outcome 6: Risk of HAE attacks (C1‐INH) – head‐to‐head trials </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Change in number of HAE attacks per week, Outcome 1: Change in number of HAE attacks per week by drug" data-id="CD013403-fig-0019" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Change in number of HAE attacks per week, Outcome 1: Change in number of HAE attacks per week by drug </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Change in number of HAE attacks per week, Outcome 2: Change in number of HAE attacks per week by drug (approved doses only)" data-id="CD013403-fig-0020" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Change in number of HAE attacks per week, Outcome 2: Change in number of HAE attacks per week by drug (approved doses only) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Change in number of HAE attacks per week, Outcome 3: Change in number of HAE attacks per week by dose (avoralstat)" data-id="CD013403-fig-0021" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Change in number of HAE attacks per week, Outcome 3: Change in number of HAE attacks per week by dose (avoralstat) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Change in number of HAE attacks per week, Outcome 4: Change in number of HAE attacks per week by dose (berotralstat)" data-id="CD013403-fig-0022" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Change in number of HAE attacks per week, Outcome 4: Change in number of HAE attacks per week by dose (berotralstat) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Change in number of HAE attacks per week, Outcome 5: Change in number of HAE attacks per week by dose (C1‐INH – all forms)" data-id="CD013403-fig-0023" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Change in number of HAE attacks per week, Outcome 5: Change in number of HAE attacks per week by dose (C1‐INH – all forms) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Change in number of HAE attacks per week, Outcome 6: Change in number of HAE attacks per week by dose (lanadelumab)" data-id="CD013403-fig-0024" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Change in number of HAE attacks per week, Outcome 6: Change in number of HAE attacks per week by dose (lanadelumab) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Change in number of HAE attacks per week, Outcome 7: Change in number of HAE attacks per week (C1‐INH) – head‐to‐head trials" data-id="CD013403-fig-0025" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Change in number of HAE attacks per week, Outcome 7: Change in number of HAE attacks per week (C1‐INH) – head‐to‐head trials </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Change in number of HAE attacks per week, Outcome 8: Change in number of HAE attacks per week (children and adolescents)" data-id="CD013403-fig-0026" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Change in number of HAE attacks per week, Outcome 8: Change in number of HAE attacks per week (children and adolescents) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Serious adverse events, Outcome 1: Risk of serious adverse events compared with placebo by drug" data-id="CD013403-fig-0027" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Serious adverse events, Outcome 1: Risk of serious adverse events compared with placebo by drug </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Serious adverse events, Outcome 2: Risk of serious adverse events – head‐to‐head trials" data-id="CD013403-fig-0028" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Serious adverse events, Outcome 2: Risk of serious adverse events – head‐to‐head trials </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Change in quality of life, Outcome 1: Change in Angioedema Quality of Life (AE‐QoL) Questionnaire scores" data-id="CD013403-fig-0029" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Change in quality of life, Outcome 1: Change in Angioedema Quality of Life (AE‐QoL) Questionnaire scores </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Change in quality of life, Outcome 2: Difference in EQ‐5D scale compared with placebo" data-id="CD013403-fig-0030" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Change in quality of life, Outcome 2: Difference in EQ‐5D scale compared with placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Change in quality of life, Outcome 3: Change in SF‐36 compared with placebo" data-id="CD013403-fig-0031" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Change in quality of life, Outcome 3: Change in SF‐36 compared with placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Change in quality of life, Outcome 4: Change in quality of life (all scales) by drug" data-id="CD013403-fig-0032" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Change in quality of life, Outcome 4: Change in quality of life (all scales) by drug </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Change in quality of life, Outcome 5: Change in AE‐QoL total score – head‐to‐head trials" data-id="CD013403-fig-0033" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Change in quality of life, Outcome 5: Change in AE‐QoL total score – head‐to‐head trials </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Difference in HAE attack severity, Outcome 1: Difference in HAE attack severity by dose (C1‐INH)" data-id="CD013403-fig-0034" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Difference in HAE attack severity, Outcome 1: Difference in HAE attack severity by dose (C1‐INH) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Difference in HAE attack severity, Outcome 2: Difference in HAE attack severity – head‐to‐head trials (C1‐INH)" data-id="CD013403-fig-0035" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Difference in HAE attack severity, Outcome 2: Difference in HAE attack severity – head‐to‐head trials (C1‐INH) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Difference in HAE attack severity, Outcome 3: Risk of a severe HAE attack by drug compared with placebo" data-id="CD013403-fig-0036" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Difference in HAE attack severity, Outcome 3: Risk of a severe HAE attack by drug compared with placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Difference in HAE attack severity, Outcome 4: Risk of a moderate HAE attack compared with placebo" data-id="CD013403-fig-0037" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Difference in HAE attack severity, Outcome 4: Risk of a moderate HAE attack compared with placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Difference in HAE attack severity, Outcome 5: Risk of a mild HAE attack compared with placebo" data-id="CD013403-fig-0038" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Difference in HAE attack severity, Outcome 5: Risk of a mild HAE attack compared with placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Difference in HAE attack severity, Outcome 6: Risk of no HAE attacks compared with placebo" data-id="CD013403-fig-0039" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Difference in HAE attack severity, Outcome 6: Risk of no HAE attacks compared with placebo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Disability, Outcome 1: Change in disability compared with placebo by drug (approved doses only) – SF‐36 scale" data-id="CD013403-fig-0040" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Disability, Outcome 1: Change in disability compared with placebo by drug (approved doses only) – SF‐36 scale </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Disability, Outcome 2: Change in disability compared with placebo by drug (approved doses only) – AE‐QoL physical functioning subscale" data-id="CD013403-fig-0041" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Disability, Outcome 2: Change in disability compared with placebo by drug (approved doses only) – AE‐QoL physical functioning subscale </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Disability, Outcome 3: Change in disability compared with placebo by drug (approved doses only) (standardised mean difference)" data-id="CD013403-fig-0042" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Disability, Outcome 3: Change in disability compared with placebo by drug (approved doses only) (standardised mean difference) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Risk of any adverse event compared with control, Outcome 1: Risk of any adverse event compared with placebo by drug" data-id="CD013403-fig-0043" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Risk of any adverse event compared with control, Outcome 1: Risk of any adverse event compared with placebo by drug </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013403-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/urn:x-wiley:14651858:media:CD013403:CD013403-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Risk of any adverse event compared with control, Outcome 2: Risk of any adverse event – head‐to‐head trials" data-id="CD013403-fig-0044" src="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_t/tCD013403-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Risk of any adverse event compared with control, Outcome 2: Risk of any adverse event – head‐to‐head trials </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/media/CDSR/CD013403/image_n/nCD013403-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013403-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Avoralstat compared with placebo for preventing hereditary angioedema attacks</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Avoralstat compared with placebo for preventing HAE attacks</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children or adults with Types I or II HAE </p> <p><b>Settings:</b> outpatient setting </p> <p><b>Intervention:</b> avoralstat </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with</b> </p> <p><b>avoralstat</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of HAE attacks</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.99</b> (0.92 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>110<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>990 per 1000</b> (920 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in number of HAE attacks</b> </p> <p>(per week)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>134</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of HAE attacks per week ranged across control groups from 0.59 to 1.27 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of HAE attacks per week in the intervention groups was <b>0.10 lower</b> (0.37 lower to 0.18 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No deaths reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.33</b> (0.01 to 7.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>13 per 1000</b> (0 to 312) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of life</b><br/>Angioedema Quality of Life scale </p> <p>(lower score is better)<br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>93</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life ranged across control groups from −0.6 to −12.14 points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention groups was <b>6.78 points lower</b> (11.61 lower to 1.95 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disability</b> </p> <p>(any validated scale)</p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.85</b> (0.62 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>24</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>830 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>706 per 1000</b> (515 to 963) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HAE:</b> hereditary angioedema; <b>N/A:</b> not applicable; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for imprecision.<br/><sup>b</sup>Downgraded one level each for imprecision and inconsistency.<br/><sup>c</sup>Downgraded two levels for imprecision and one level for indirectness. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Avoralstat compared with placebo for preventing hereditary angioedema attacks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013403-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Berotralstat compared with placebo or active control for preventing hereditary angioedema attacks</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Berotralstat compared with placebo or active control for preventing HAE attacks</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children or adults with Types I or II HAE </p> <p><b>Settings:</b> outpatient setting </p> <p><b>Intervention:</b> berotralstat </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with berotralstat</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of HAE attacks</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.63</b> (0.39 to 1.00) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>37</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>910 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>573 per 1000</b> (355 to 910) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in number of HAE attacks</b> </p> <p>(per week)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>130</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks per week ranged across control groups from 0.55 to 0.95</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks per week in the intervention groups was <b>0.39 attacks lower</b> (0.74 lower to 0.05 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No deaths reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.77</b> (0.02 to 24.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>128<br/>(3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>35 per 1000</b> (1 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of life</b><br/>Angioedema Quality of Life scale<br/>(lower score is better)<br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>130</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life ranged across control groups from 3.18 points to −9.69 points </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention group was <b>15.28 points lower</b> (29.42 lower to 1.14 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disability</b><br/>Standardised mean difference </p> <p>(lower is better)</p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability ranged across control groups from 1.51 to −1.95</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability in the intervention groups was <b>1.01 units lower</b> (1.62 lower to 0.40 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.03</b> (0.88 to 1.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>128</p> <p>(3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>761 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>784 per 1000</b> (670 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HAE:</b> hereditary angioedema; <b>N/A:</b> not applicable; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision.<br/><sup>b</sup>Downgraded one level for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Berotralstat compared with placebo or active control for preventing hereditary angioedema attacks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013403-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>C1‐INH compared with placebo or active control for preventing HAE attacks</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children or adults with Types I or II HAE </p> <p><b>Settings:</b> outpatient setting </p> <p><b>Intervention:</b> C1‐INH(SC) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with C1‐INH(SC)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of HAE attacks</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.29</b> (0.16 to 0.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>43<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>810 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>24 per 1000</b> (0 to 162) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in number of HAE attacks</b> </p> <p>(per week)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>45 <br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of HAE attacks per week in the control group was 0.93</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of HAE attacks per week in the intervention group was <b>0.81 lower</b> (0.98 lower to 0.64 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No deaths reported</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.34</b> (0.01 to 8.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>44<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>23 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b> (0 to 187) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of life</b><br/>standardised mean difference </p> <p>(lower is better)</p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>36</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the control group was −0.87 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention groups was <b>0.29 units lower</b> (0.76 lower to 0.18 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disability</b> </p> <p>(any validated scale)</p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.03</b> (0.84 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>44</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/><b>Moderate</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>663 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>683 per 1000</b> (557 to 842) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>C1‐INH(SC):</b> subcutaneous C1 esterase inhibitor; <b>CI:</b> confidence interval; <b>HAE:</b> hereditary angioedema; <b>N/A:</b> not applicable; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision.<br/><sup>b</sup>Downgraded three levels for imprecision.<br/><sup>c</sup>Downgraded one level for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013403-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Plasma‐derived C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>pdC1‐INH compared with placebo or active control for preventing HAE attacks</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children or adults with Types I or II HAE </p> <p><b>Settings:</b> outpatient setting </p> <p><b>Intervention:</b> pdC1‐INH </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with pdC1‐INH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of HAE attacks</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in number of HAE attacks</b> </p> <p>(per week)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>71</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks per week in the control group was 0.9</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks per week in the intervention group was <b>0.53 attacks lower</b> (0.58 lower to 0.48 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No deaths reported</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.54</b> (0.09 to 3.10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>71<br/>(1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> (5 to 164) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of life</b><br/>Angioedema Quality of Life Score<br/>(lower score is better) </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>31</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the control group was −6.86</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention group was <b>3.49 points lower</b> (10.86 lower to 3.88 higher) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disability</b><br/>(any validated scale) </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.05</b> (0.78 to 1.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>71</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>561 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>589 per 1000</b> (438 to 797) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HAE:</b> hereditary angioedema; <b>N/A:</b> not applicable; <b>pdC1‐INH:</b> plasma‐derived C1 esterase inhibitor; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision.<br/><sup>b</sup>Downgraded three levels for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Plasma‐derived C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013403-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Nanofiltered C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>C1‐INH‐nf compared with placebo or active control for preventing HAE attacks</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children or adults with Types I or II HAE </p> <p><b>Settings:</b> outpatient setting </p> <p><b>Intervention:</b> C1‐INH‐nf </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with C1‐INH‐nf</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of HAE attacks</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in number of HAE attacks</b> </p> <p>(per week)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>22</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of HAE attacks per week in the control group was 1.06</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of HAE attacks per week in the intervention group was <b>0.53 lower</b> (0.78 lower to 0.28 attacks per week lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No deaths reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of life</b><br/>standardised mean difference </p> <p>(lower is better)</p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the control group was 4.85 units</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention group was <b>0.91 units lower</b> (1.64 lower to 0.18 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disability</b> </p> <p>standardised mean difference</p> <p>(lower is better)</p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>16</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability in the control group was −0.71</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability in the intervention group was <b>0.84 units lower</b> (1.57 lower to 0.12 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>C1‐INH‐nf:</b> nanofiltered C1 esterase inhibitor; <b>CI:</b> confidence interval; <b>HAE:</b> hereditary angioedema; <b>N/A:</b> not applicable; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Nanofiltered C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013403-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Recombinant human C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>rhC1‐INH compared with placebo or active control for preventing HAE attacks</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children or adults with Types I or II HAE </p> <p><b>Settings:</b> outpatient setting </p> <p><b>Intervention:</b> rhC1‐INH </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with rhC1‐INH</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of HAE attacks</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in number of HAE attacks</b> </p> <p>(per week)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>32</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks in the control group was 1.8 per week</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks per week in the intervention groups was <b>0.92 attacks lower</b> (1.31 lower to 0.53 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No deaths reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.50</b> (0.06 to 34.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>29</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No events reported in the placebo group, 1 event reported in the rhC1‐INH group.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of life</b><br/>standardised mean difference<br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disability</b><br/>(any validated scale)<br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.39</b> (0.71 to 2.70) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>29</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>398 per 1000</b> (203 to 772) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HAE:</b> hereditary angioedema; <b>N/A:</b> not applicable; <b>rhC1‐INH:</b> recombinant human C1 esterase inhibitor; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels for imprecision.<br/><sup>b</sup>Downgraded two levels for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Recombinant human C1 esterase inhibitor compared with placebo or active control for preventing hereditary angioedema attacks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD013403-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Lanadelumab compared with placebo or active control for preventing hereditary angioedema attacks</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Lanadelumab compared with placebo or active control for preventing HAE attacks</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children or adults with Types I or II HAE </p> <p><b>Settings:</b> outpatient setting </p> <p><b>Intervention:</b> lanadelumab </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lanadelumab</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Risk of HAE attacks</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Outcome not reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in number of HAE attacks</b> </p> <p>(per week)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>83</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks per week ranged across control groups from 0.37 to 0.49</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The number of HAE attacks per week in the intervention groups was <b>0.41 attacks lower</b> (0.48 lower to 0.35 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Mortality</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>N/A</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No deaths reported.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>N/A</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Serious adverse events</b> </p> <p>(during follow‐up)</p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.88</b> (0.08 to 10.39) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>162</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>24 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>73 per 1000</b> (7 to 765) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Quality of life</b><br/>standardised mean difference<br/>(lower is better)<br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>68</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the control group was −4.72 points</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life in the intervention group was <b>0.91 units lower</b> (1.43 lower to 0.40 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Disability</b><br/>Standardised mean difference<br/>(lower is better)<br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>64</p> <p>(1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability in the control group was −5.42</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability in the intervention group was <b>1.38 units lower</b> (1.94 lower to 0.82 lower) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b><br/>(during follow‐up) </p> </td> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Study population</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.07</b> (0.77 to 1.47) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>158</p> <p>(2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>840 per 1000</b> (710 to 980) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HAE:</b> hereditary angioedema; <b>N/A:</b> not applicable; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for imprecision. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Lanadelumab compared with placebo or active control for preventing hereditary angioedema attacks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013403-tbl-0008"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Hereditary angioedema nomenclature</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Abbreviation used in this review</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Other abbreviations used in the literature</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type I HAE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type 1 HAE; HAE type 1; C1‐INH‐HAE (type 1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type II HAE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type 2 HAE; HAE type 2; C1‐INH‐HAE (type 2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type III HAE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Type 3 HAE; HAE type 3; C1‐INH‐HAE (type 3)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p>C1‐INH: C1 esterase inhibitor; HAE: hereditary angioedema.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Hereditary angioedema nomenclature</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013403-tbl-0009"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Drugs for the prevention of hereditary angioedema attacks</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Drug</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Brand</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Route of administration</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Avoralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not approved</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berotralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Orladeyo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1‐INH(SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haegarda</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SC</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1‐INH‐nf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cinryze</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravenous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pdC1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berinert</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravenous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>rhC1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ruconest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intravenous</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Danazol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Danocrine/Cyclomen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lanadelumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Takhzyro</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SC</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tranexamic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lysteda</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>C1‐INH: C1 esterase inhibitor; C1‐INH‐nf: nanofiltered C1 esterase inhibitor; C1‐INH(SC): subcutaneous C1 esterase inhibitor; HAE: hereditary angioedema; pdC1‐INH: plasma‐derived C1 esterase inhibitor; rhC1‐INH: recombinant human C1 esterase inhibitor. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Drugs for the prevention of hereditary angioedema attacks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/full#CD013403-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013403-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Risk of hereditary angioedema (HAE) attacks</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Risk of HAE attacks by drug vs placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Avoralstat (all doses)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Berotralstat (all doses)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.65, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 C1‐INH(SC) (all doses)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.21, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Risk of HAE attacks by drug (approved doses only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Avoralstat (not approved)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.92, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Berotralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.39, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 C1‐INH(SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.16, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Risk of HAE attacks by dose (avoralstat) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Avoralstat 300 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.90, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Avoralstat 500 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.91, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Risk of HAE attacks by dose (berotralstat) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Berotralstat 62.5 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.84, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Berotralstat 125 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.39, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 Berotralstat 250 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.66, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.4 Berotralstat 350 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.45, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Risk of HAE attacks by dose (C1‐INH(SC)) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 C1‐INH(SC) 40 IU/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.19, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 C1‐INH(SC) 60 IU/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.16, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Risk of HAE attacks (C1‐INH) – head‐to‐head trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.60, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Risk of hereditary angioedema (HAE) attacks</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013403-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Change in number of HAE attacks per week</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Change in number of HAE attacks per week by drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Avoralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.37, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Berotralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.45, ‐0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 C1‐INH(SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.83 [‐0.98, ‐0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 pdC1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐0.58, ‐0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.5 C1‐INH‐nf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐0.78, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.6 rhC1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.92 [‐1.31, ‐0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.7 lanadelumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.38 [‐0.45, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Change in number of HAE attacks per week by drug (approved doses only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Avoralstat (not approved)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.37, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Berotralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.74, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 C1‐INH(SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.81 [‐0.98, ‐0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.4 C1‐INH‐nf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐0.78, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.5 pdC1‐INH (not approved)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐0.58, ‐0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.6 rhC1‐INH (not approved)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.92 [‐1.31, ‐0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.7 Lanadelumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐0.48, ‐0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Change in number of HAE attacks per week by dose (avoralstat) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 300 mg 3 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.10, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 400 mg 3 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.75, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 500 mg 3 times/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.19, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Change in number of HAE attacks per week by dose (berotralstat) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.40, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 100–149 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.74, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 150 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.37, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.4 250 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐0.65, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.5 350 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐0.64, ‐0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Change in number of HAE attacks per week by dose (C1‐INH – all forms) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 2000 IU twice per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐0.58, ‐0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 1000 IU twice per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐0.78, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.3 60 IU/kg twice per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.81 [‐0.98, ‐0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.4 50 IU/kg twice per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.11 [‐1.52, ‐0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.5 50 IU/kg once per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐1.16, ‐0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.6 40 IU/kg twice per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.01 [‐1.58, ‐0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Change in number of HAE attacks per week by dose (lanadelumab) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 150 mg every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.46, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 300 mg every 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.36 [‐0.45, ‐0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 300 mg every 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐0.48, ‐0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Change in number of HAE attacks per week (C1‐INH) – head‐to‐head trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 C1‐INH high dose vs low dose (all forms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.15 [‐0.27, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Change in number of HAE attacks per week (children and adolescents) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Children (C1‐INH‐nf 1000 IU vs 500 IU)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.36, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 Adolescents (lanadelumab vs placebo)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.38, 0.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Change in number of HAE attacks per week</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013403-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Serious adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Risk of serious adverse events compared with placebo by drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Avoralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Berotralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.02, 24.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 C1‐INH‐nf</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 C1‐INH(SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.5 pdC1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.09, 3.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.6 rhC1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.06, 34.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.7 Lanadelumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.08, 10.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Risk of serious adverse events – head‐to‐head trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Short‐term trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Long‐term trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.32, 4.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013403-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Change in quality of life</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Change in Angioedema Quality of Life (AE‐QoL) Questionnaire scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Avoralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.78 [‐11.61, ‐1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Berotralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.28 [‐29.42, ‐1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 pdC1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.37 [‐23.47, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.4 Lanadelumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐14.91 [‐21.89, ‐7.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Difference in EQ‐5D scale compared with placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.90 [2.87, 14.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Change in SF‐36 compared with placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.04 [2.32, 15.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Change in quality of life (all scales) by drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Avoralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐0.84, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Berotralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.86 [‐1.67, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 C1‐INH (all forms)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.75, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.4 Lanadelumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.91 [‐1.43, ‐0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Change in AE‐QoL total score – head‐to‐head trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 C1‐INH(SC) + rh hyaluronidase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.29, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 C1‐INH(SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐0.20, 0.62]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Change in quality of life</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013403-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Difference in HAE attack severity</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Difference in HAE attack severity by dose (C1‐INH) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 40 IU/kg twice per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.49, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 60 IU/kg twice per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.52, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.3 1000 IU twice per week</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐0.99, ‐0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Difference in HAE attack severity – head‐to‐head trials (C1‐INH) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐1.08, 0.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Risk of a severe HAE attack by drug compared with placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 C1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.14, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 Lanadelumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.05, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Risk of a moderate HAE attack compared with placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 C1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [0.83, 2.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 Lanadelumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.35, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Risk of a mild HAE attack compared with placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 C1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.08 [0.67, 14.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 Lanadelumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.56 [0.50, 41.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Risk of no HAE attacks compared with placebo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 C1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.37 [2.24, 8.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.2 Lanadelumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.22 [2.51, 132.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Difference in HAE attack severity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013403-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Disability</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Change in disability compared with placebo by drug (approved doses only) – SF‐36 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.80 [1.36, 12.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Change in disability compared with placebo by drug (approved doses only) – AE‐QoL physical functioning subscale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Berotralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐22.50 [‐34.91, ‐10.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Lanadelumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐30.55 [‐37.55, ‐23.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Change in disability compared with placebo by drug (approved doses only) (standardised mean difference) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.1 C1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.84 [‐1.57, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.2 Berotralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.01 [‐1.62, ‐0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3.3 Lanadelumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.38 [‐1.94, ‐0.82]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Disability</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013403-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Risk of any adverse event compared with control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Risk of any adverse event compared with placebo by drug <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Avoralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.62, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 Berotralstat</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.88, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.3 C1‐INH(SC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.84, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.4 pdC1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.78, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.5 rhC1‐INH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.71, 2.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.6 Lanadelumab</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.77, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Risk of any adverse event – head‐to‐head trials <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>333</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.96, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Short‐term trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.98, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 Long‐term trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.81, 1.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Risk of any adverse event compared with control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013403.pub2/references#CD013403-tbl-0016">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013403.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013403-note-0021">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013403-note-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013403-note-0019">Français</a> </li> <li class="section-language"> <a class="" href="hu#CD013403-note-0020">Magyar</a> </li> <li class="section-language"> <a class="" href="ko#CD013403-note-0015">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013403-note-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013403-note-0018">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013403-note-0013">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013403-note-0014">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013403\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013403\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013403\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013403\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013403\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9mpoajSI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013403.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013403.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013403.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013403.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013403.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728292225"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013403.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728292229"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013403.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec0ea7e41f46e',t:'MTc0MDcyODI5Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 